

FILE 'REGISTRY' ENTERED AT 14:08:06 ON 07 AUG 2003

L1 0 S ACETAMINOOPHEN
L2 130 S ACETAMINOPHEN

FILE 'CA' ENTERED AT 14:08:53 ON 07 AUG 2003

E HOMOCYSTENE
E HOMOCYSTEINE
L3 7530 S E3
L4 0 S L1
L5 10702 S L2
L6 9 S L5 AND L3

FILE 'CAPLUS' ENTERED AT 14:11:10 ON 07 AUG 2003

L7 9 S L2 AND L3
E PLAQUE
L8 21528 S E3
L9 43 S L8 AND L3
L10 6 S L5 AND L8
E VASCULAR
L11 114286 S E3
L12 52 S L11 AND L5
L13 5160 S COX-2

=> e atherosclerosis

E1 1 ATHEROSCLEROSIA/BI
E2 4 ATHEROSCLEROSIC/BI
E3 35977 --> ATHEROSCLEROSIS/BI
E4 1 ATHEROSCLEROSIS8/BI
E5 1 ATHEROSCLEROSISARE/BI
E6 1 ATHEROSCLEROSISATHEROSCLEROSIS/BI
E7 1 ATHEROSCLEROSISHATHEROSCLEROSIS/BI
E8 1 ATHEROSCLEROSOIS/BI
E9 2 ATHEROSCLEROSOS/BI
E10 1 ATHEROSCLEROSS/BI
E11 2 ATHEROSCLEROSTIC/BI
E12 1 ATHEROSCLEROT/BI

=> s e3

L14 35977 ATHEROSCLEROSIS/BI

=> s l13 and l14

L15 104 L13 AND L14

=> d l15 50-104

L15 ANSWER 50 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:594628 CAPLUS

DN 137:150265

TI Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors,
compositions and methods of use

IN Khanapure, Subhash P.; Garvey, David S.; Earl, Richard A.; Ezawa, Maiko;
Fang, Xinqin; Gaston, Ricky D.

PA Nitromed, Inc., USA

SO PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060378	A2	20020808	WO 2001-US48823	20011221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
 UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002119977 A1 20020829 US 2001-24046 20011221
 PRAI US 2000-256932P P 20001221
 OS MARPAT 137:150265

L15 ANSWER 51 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:529732 CAPLUS
 DN 137:167426
 TI Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via
 nuclear factor- κ B/I κ B- and ERK2-dependent mechanisms
 AU Eligini, Sonia; Brambilla, Marta; Banfi, Cristina; Camera, Marina; Sironi,
 Luigi; Barbieri, Silvia Stella; Auwerx, Johan; Tremoli, Elena; Colli,
 Susanna
 CS Department of Pharmacological Sciences, University of Milan, E. Grossi
 Paoletti Center, Milan, 20133, Italy
 SO Cardiovascular Research (2002), 55(2), 406-415
 CODEN: CVREAU; ISSN: 0008-6363
 PB Elsevier Science B.V.
 DT Journal
 LA English
 RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 52 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:475973 CAPLUS
 DN 137:367650
 TI Expression of COX-1 and **COX-2** mRNAs in atherosclerotic
 plaques
 AU McGeer, Patrick L.; McGeer, Edith G.; Yasojima, Koji
 CS Department of Psychiatry, Kinsmen Laboratory of Neurological Research,
 University of British Columbia, Vancouver, BC, V6T 1Z3, Can.
 SO Experimental Gerontology (2002), 37(7), 925-929
 CODEN: EXGEAB; ISSN: 0531-5565
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 53 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:472087 CAPLUS
 DN 137:91836
 TI Oxidized low-density and high-density lipoproteins regulate the production
 of matrix metalloproteinase-1 and -9 by activated monocytes
 AU Ardans, Jeanette A.; Economou, Antaeus P.; Martinson, James M., Jr.; Zhou,
 Min; Wahl, Larry M.
 CS Immunopathology Section, National Institute of Dental and Craniofacial
 Research, National Institutes of Health, Bethesda, MD, 20892-4352, USA
 SO Journal of Leukocyte Biology (2002), 71(6), 1012-1018
 CODEN: JLBIE7; ISSN: 0741-5400
 PB Federation of American Societies for Experimental Biology
 DT Journal
 LA English
 RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 54 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:417397 CAPLUS
 DN 137:108256
 TI Induction of cyclooxygenase-2 and enhanced release of prostaglandin E2 and I2 in human endothelial cells by engagement of CD40
 AU Garlichs, Christoph D.; Geis, Tobias; Goppelt-Struebe, Margarete; Eskafi, Saeed; Schmidt, Andrej; Schulze-Koops, Hendrik; Ludwig, Josef; Daniel, Werner G.; Schmeisser, Alexander
 CS Medical Clinic II, Friedrich-Alexander-University Erlangen-Nurnberg, Erlangen, Germany
 SO Atherosclerosis (Shannon, Ireland) (2002), 163(1), 9-16
 CODEN: ATHSBL; ISSN: 0021-9150
 PB Elsevier Science Ireland Ltd.
 DT Journal
 LA English
 RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 55 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:392746 CAPLUS
 DN 137:230388
 TI Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice
 AU Burleigh, Michael E.; Babaev, Vladimir R.; Oates, John A.; Harris, Raymond C.; Gautam, Shiva; Riendeau, Denis; Marnett, Lawrence J.; Morrow, Jason D.; Fazio, Sergio; Linton, MacRae F.
 CS Cardiovascular Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37232-6300, USA
 SO Circulation (2002), 105(15), 1816-1823
 CODEN: CIRCAZ; ISSN: 0009-7322
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 56 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:179098 CAPLUS
 DN 137:15839
 TI Eicosanoids
 AU Watanabe, Tsuyoshi
 CS Third Department of Internal Medicine, Fukushima Medical College, Japan
 SO Annual Review Naibunpi, Taisha (2002) 282-288
 CODEN: ARNTC7
 PB Chugai Igakusha
 DT Journal; General Review
 LA Japanese

L15 ANSWER 57 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:107825 CAPLUS
 DN 136:156529
 TI Molecularly imprinted polymers for the treatment and diagnosis of medical conditions
 IN Green, Bernard S.; Priwler, Morris
 PA Israel
 SO U.S. Pat. Appl. Publ., 15 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002015690	A1	20020207	US 2001-893643	20010629
PRAI	US 2000-215882P	P	20000630		

L15 ANSWER 58 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:86839 CAPLUS
 DN 136:261050
 TI Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty
 AU Connolly, Elizabeth; Bouchier-Hayes, David J.; Kaye, Elaine; Leahy, Austin; Fitzgerald, Desmond; Belton, Orina
 CS Departments of Clinical Pharmacology and Surgery, Royal College of Surgeons in Ireland, Dublin, Ire.
 SO Journal of Pharmacology and Experimental Therapeutics (2002), 300(2), 393-398
 CODEN: JPETAB; ISSN: 0022-3565
 PB American Society for Pharmacology and Experimental Therapeutics
 DT Journal
 LA English
 RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 59 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:82983 CAPLUS
 DN 136:277167
 TI Secretory phospholipase A2 elicits proinflammatory changes and upregulates the surface expression of Fas ligand in monocytic cells. Potential relevance for atherogenesis
 AU Hernandez, Marita; Fuentes, Lucia; Aviles, Francisco Javier Fernandez; Crespo, Mariano Sanchez; Nieto, Maria Luisa
 CS Instituto de Biologia Genetica Molecular, Facultad de Medicina, Hospital Clinico Universitario, Valladolid, Spain
 SO Circulation Research (2002), 90(1), 38-45
 CODEN: CIRUAL; ISSN: 0009-7330
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 60 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:42112 CAPLUS
 DN 137:3850
 TI Cyclooxygenase-2 and **atherosclerosis**: friend or foe?
 AU Massy, Ziad A.; Swan, Suzanne K.
 CS Necker Hospital and CH Beauvais, Paris, Fr.
 SO Nephrology, Dialysis, Transplantation (2001), 16(12), 2286-2289
 CODEN: NDTREA; ISSN: 0931-0509
 PB Oxford University Press
 DT Journal; General Review
 LA English
 RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 61 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:3654 CAPLUS
 DN 137:134186
 TI Advances in research and bioactivities of compounds containing di-tert-butylphenol
 AU Xu, Zhibin; Guo, Zongru
 CS Institute of Materia Medica, Chinese Academy of Medical Sciences and

Peking Union Medical College, Beijing, 100050, Peop. Rep. China
 SO Yaoxue Xuebao (2001), 36(11), 877-880
 CODEN: YHHPAL; ISSN: 0513-4870
 PB Yaoxue Xuebao Bianjibu
 DT Journal; General Review
 LA English
 RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 62 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:2206 CAPLUS
 DN 136:395732
 TI Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model
 of **atherosclerosis** and in cultured vascular smooth muscle cells
 AU Hernandez-Presa, Miguel Angel; Martin-Ventura, Jose Luis; Ortego, Monica;
 Gomez-Hernandez, Almudena; Tunon, Jose; Hernandez-Vargas, Purificacion;
 Blanco-Colio, Luis Miguel; Mas, Sebastian; Aparicio, Cesar; Ortega, Luis;
 Vivanco, Fernando; Gerique, Juan Gomez; Diaz, Cristina; Hernandez,
 Gonzalo; Egido, J.
 CS Autonoma University, Fundacion Jimenez Diaz, Vascular Research Laboratory,
 Madrid, 28040, Spain
 SO Atherosclerosis (Shannon, Ireland) (2002), 160(1), 49-58
 CODEN: ATHSBL; ISSN: 0021-9150
 PB Elsevier Science Ireland Ltd.
 DT Journal
 LA English
 RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 63 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:868218 CAPLUS
 DN 136:694
 TI Thromboxane inhibitors, compositions, and methods for therapeutic use
 IN Saenz de Tejada, Inigo
 PA Nitromed, Inc., USA
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001089519	A1	20011129	WO 2001-US16318	20010522
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
	UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003050305	A1	20030313	US 2002-285620	20021101
PRAI	US 2000-205536P	P	20000522		
	WO 2001-US16318	A1	20010522		
OS	MARPAT 136:694				
RE.CNT	3				
	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD				
	ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L15 ANSWER 64 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:721272 CAPLUS
 DN 136:84447

TI Inhibition of the mitogen activated protein kinase, p38.alpha., prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loading
AU Feng, Y.; Schreiner, G. F.; Chakravarty, S.; Liu, D. Y.; Joly, A. H.
CS Scios Inc., Sunnyvale, CA, 94086, USA
SO Atherosclerosis (Shannon, Ireland) (2001), 158(2), 331-338
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 65 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:696514 CAPLUS
DN 136:245457
TI Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability
AU Cipollone, Francesco; Prontera, Cesaria; Pini, Barbara; Marini, Matteo; Fazia, Maria; De Cesare, Domenico; Iezzi, Annalisa; Uchino, Sante; Boccoli, Gianfranco; Saba, Vittorio; Chiarelli, Francesco; Cuccurullo, Franco; Mezzetti, Andrea
CS G. D'Annunzio School of Medicine, University of Chieti, Chieti, Italy
SO Circulation (2001), 104(8), 921-927
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 66 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:682455 CAPLUS
DN 136:346
TI Risk of cardiovascular events associated with selective COX-2 inhibitors
AU Mukherjee, Debabrata; Nissen, Steven E.; Topol, Eric J.
CS Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH, 44195, USA
SO JAMA, the Journal of the American Medical Association (2001), 286(8), 954-959
CODEN: JAMAAP; ISSN: 0098-7484
PB American Medical Association
DT Journal
LA English
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 67 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:567013 CAPLUS
DN 136:272854
TI A pleiotropic antiatherogenic action of ibuprofen
AU Zapolska-Downar, Danuta; Naruszewicz, Marek
CS Regional Center for Atherosclerosis Research, Pomeranian Medical University, Szczecin, 70-111, Pol.
SO Medical Science Monitor (2001), 7(4), 837-841
CODEN: MSMOFR; ISSN: 1234-1010
PB Medical Science International Publishing
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 68 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:567010 CAPLUS
 DN 135:303402
 TI My life and times with enzymes and mediators
 AU Vane, John R.
 CS The William Harvey Research Institute, The William Harvey Research
 Foundation, London, EC1M 6BQ, UK
 SO Medical Science Monitor (2001), 7(4), 790-800
 CODEN: MSMOFR; ISSN: 1234-1010
 PB Medical Science International Publishing
 DT Journal; General Review
 LA English
 RE.CNT 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 69 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:537047 CAPLUS
 DN 136:326
 TI Effects of **COX-2** inhibitors on aortic prostacyclin
 production in cholesterol-fed rabbits
 AU Wong, E.; Huang, J.; Tagari, P.; Riendeau, D.
 CS Department of Biochemistry & Molecular Biology, Merck Frosst Centre for
 Therapeutic Research, Kirkland, QC, H9H 3L1, Can.
 SO Atherosclerosis (Shannon, Ireland) (2001), 157(2), 393-402
 CODEN: ATHSBL; ISSN: 0021-9150
 PB Elsevier Science Ireland Ltd.
 DT Journal
 LA English
 RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 70 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:471054 CAPLUS
 DN 135:209787
 TI The orphan nuclear receptor ROR.alpha. is a negative regulator of the
 inflammatory response
 AU Delerive, Philippe; Monte, Didier; Dubois, Guillaume; Trottein, Francois;
 Fruchart-Najib, Jamila; Mariani, Jean; Fruchart, Jean-Charles; Staels,
 Bart
 CS INSERM U325, Departement d'Atherosclerose, Institut Pasteur de Lille,
 Lille, 59019, Fr.
 SO EMBO Reports (2001), 2(1), 42-48
 CODEN: ERMEAX; ISSN: 1469-221X
 PB Oxford University Press
 DT Journal
 LA English
 RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 71 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:416325 CAPLUS
 DN 135:255667
 TI Approaches to rheumatoid arthritis in 2000
 AU Wollheim, Frank A.
 CS Department of Rheumatology, University of Lund, Lund, SE 221 85, Swed.
 SO Current Opinion in Rheumatology (2001), 13(3), 193-201
 CODEN: CORHES; ISSN: 1040-8711
 PB Lippincott Williams & Wilkins
 DT Journal; General Review
 LA English

RE.CNT 113 THERE ARE 113 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 72 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:289726 CAPLUS
DN 135:220416
TI Cyclooxygenase products and atherothrombosis
AU FitzGerald, Garret A.; Austin, Sandra; Egan, Karine; Cheng, Yan; Pratico, Domenico
CS Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, PA, USA
SO Annals of Medicine (Helsinki, Finland) (2000), 32(Suppl. 1), 21-26
CODEN: ANMDEU; ISSN: 0785-3890
PB Royal Society of Medicine Press Ltd.
DT Journal; General Review
LA English

RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 73 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:286826 CAPLUS
DN 134:348558
TI Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation
AU Gryglewski, Ryszard J.; Chlopicki, Stefan; Uracz, Wojciech; Marcinkiewicz, Ewa
CS Chair of Pharmacology, Jagiellonian University, Krakow, Pol.
SO Medical Science Monitor (2001), 7(1), 1-16
CODEN: MSMOFR; ISSN: 1234-1010
PB Medical Science International Publishing
DT Journal
LA English

RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 74 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:222650 CAPLUS
DN 135:14164
TI Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor Knockout mice
AU Pratico, Domenico; Tillmann, Cyrus; Zhang, Zhi-Bing; Li, Hongwei; FitzGerald, Garret A.
CS Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, 19104-6160, USA
SO Proceedings of the National Academy of Sciences of the United States of America (2001), 98(6), 3358-3363
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English

RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 75 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:196401 CAPLUS
DN 134:290645
TI Serotonin-induced human coronary microvascular contraction during acute myocardial ischemia is blocked by COX-2 inhibition
AU Metais, Caroline; Bianchi, Cesario; Li, Jianyi; Li, Jian; Simons, Michael; Sellke, Frank W.
CS Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA

SO Basic Research in Cardiology (2001), 96(1), 59-67
 CODEN: BRCAB7; ISSN: 0300-8428
 PB Steinkopff Verlag
 DT Journal
 LA English
 RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 76 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:170534 CAPLUS
 DN 135:150311
 TI Signaling Mechanism Underlying COX-2 Induction by
 Lysophosphatidylcholine
 AU Rikitake, Yoshiyuki; Hirata, Ken-ichi; Kawashima, Seinosuke; Takeuchi,
 Shigeto; Shimokawa, Yasushi; Kojima, Yoko; Inoue, Nobutaka; Yokoyama,
 Mitsuhiro
 CS First Department of Internal Medicine, Kobe University School of Medicine,
 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
 SO Biochemical and Biophysical Research Communications (2001), 281(5),
 1291-1297
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic Press
 DT Journal
 LA English
 RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 77 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:101337 CAPLUS
 DN 134:157560
 TI Recombinant adeno-associated virus (rAAV) expressing proteins involved in
 preventing cell proliferation, thrombosis, and/or cell migration in a
 vascular graft
 IN Zoldhelyi, Pierre; Willerson, James T.; Cunningham, Janet
 PA Avigen, Inc., USA; University of Texas System Board of Regents
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001009360	A1	20010208	WO 2000-US21194	20000802
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB,				
	GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,				
	LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,				
	NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT,				
	TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002192188	A1	20021219	US 2002-215164	20020807
PRAI	US 1999-146886P	P	19990802		
	US 2000-634729	A1	20000802		
RE.CNT	10				
	THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD				
	ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L15 ANSWER 78 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:45808 CAPLUS
 DN 134:276081
 TI Group X secretory phospholipase A2 induces potent productions of various

lipid mediators in mouse peritoneal macrophages
AU Saiga, A.; Morioka, Y.; Ono, T.; Nakano, K.; Ishimoto, Y.; Arita, H.;
Hanasaki, K.
CS Shionogi Research Laboratories, Shionogi&Co., Ltd., Fukushima-ku, Osaka,
553-0002, Japan
SO Biochimica et Biophysica Acta (2001), 1530(1), 67-76
CODEN: BBACAQ; ISSN: 0006-3002
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 79 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:640645 CAPLUS
DN 134:129492
TI Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with
atherosclerosis
AU Belton, Orina; Byrne, Dara; Kearney, Dermot; Leahy, Austin; Fitzgerald,
Desmond J.
CS Departments of Clinical Pharmacology and Surgery, Royal College of
Surgeons in Ireland, Dublin, 2, Ire.
SO Circulation (2000), 102(8), 840-845
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 80 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:507751 CAPLUS
DN 133:218084
TI Cholesterol modulates vascular reactivity to endothelin-1 by stimulating a
pro-inflammatory pathway
AU Paris, Daniel; Town, Terrence; Humphrey, James; Yokota, Kiyoko; Mullan,
Michael
CS Roskamp Institute, University of South Florida, Tampa, FL, 33613, USA
SO Biochemical and Biophysical Research Communications (2000), 274(2),
553-558
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 81 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:457190 CAPLUS
DN 133:85122
TI Expression vectors comprising multiple shear stress responsive elements
(SSRE) and a gene of interest and modulating vasculogenesis and/or
angiogenesis
IN Resnick, Nitzan
PA Florence Medical Ltd., Israel
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2000039275 A2 20000706 WO 1999-IL702 19991223
 WO 2000039275 A3 20001026
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 6440726 B1 20020827 US 1998-220510 19981224
 AU 2000017954 A5 20000731 AU 2000-17954 19991223
 EP 1141266 A2 20011010 EP 1999-961261 19991223
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 JP 2002533113 T2 20021008 JP 2000-591168 19991223
 PRAI US 1998-113863P P 19981224
 US 1998-220510 A 19981224
 US 1998-220510P P 19981224
 WO 1999-IL702 W 19991223

L15 ANSWER 82 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:450705 CAPLUS
 DN 133:320212
 TI Endothelial dysfunction, hemodynamic forces, and atherogenesis
 AU Gimbrone, Michael A., Jr.; Topper, James N.; Nagel, Tobi; Anderson, Keith
 R.; Garcia-Cardena, Guillermo
 CS Vascular Research Division, Brigham and Women's Hospital, Boston, MA,
 02115-5817, USA
 SO Annals of the New York Academy of Sciences (2000), 902(Atherosclerosis V,
 The Fifth Sarasota International Conference, 1999), 230-240
 CODEN: ANYAA9; ISSN: 0077-8923
 PB New York Academy of Sciences
 DT Journal; General Review
 LA English
 RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 83 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:222689 CAPLUS
 DN 133:308930
 TI Cyclooxygenase-2 regulates granulocyte-macrophage colony-stimulating
 factor, but not interleukin-8, production by human vascular cells: role of
 cAMP
 AU Stanford, Salome J.; Pepper, John R.; Mitchell, Jane A.
 CS Unit of Critical Care, The Royal Brompton and Harefield N.H.S. Trust,
 Imperial College School of Medicine, London, SW3 6NP, UK
 SO Arteriosclerosis, Thrombosis, and Vascular Biology (2000), 20(3), 677-682
 CODEN: ATVBFA; ISSN: 1079-5642
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 84 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:218219 CAPLUS
 DN 133:118300
 TI Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human
 aortic atherosclerotic lesions
 AU Hong, Bum Kee; Kwon, Hyuck Moon; Lee, Byoung Kwon; Kim, Dongsoo; Kim, In

Jai; Kang, Seok-Min; Jang, Yangsoo; Cho, Sang Ho; Kim, Hae Kyoony; Jang, Byung Chul; Cho, Seung-Yun; Kim, Hyun-Seung; Kim, Myung Sin; Kwon, Hyuck Chan; Lee, Namho

CS Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 135-270, S. Korea

SO Yonsei Medical Journal (2000), 41(1), 82-88
CODEN: YOMJA9; ISSN: 0513-5796

PB Yonsei University College of Medicine

DT Journal

LA English

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 85 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:183592 CAPLUS

DN 132:320769

TI Release of GM-CSF and G-CSF by human arterial and venous smooth muscle cells: differential regulation by **COX-2**

AU Stanford, Salome J.; Pepper, John R.; Mitchell, Jane A.

CS Unit of Critical Care, Imperial College School of Medicine, The Royal Brompton and Harefield N.H.S. Trust, London, SW3 6NP, UK

SO British Journal of Pharmacology (2000), 129(5), 835-838
CODEN: BJPCBM; ISSN: 0007-1188

PB Nature Publishing Group

DT Journal

LA English

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 86 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:148522 CAPLUS

DN 132:261603

TI Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NF- κ B

AU Yan, Zhaoping; Subbaramaiah, Kotha; Camilli, Tura; Zhang, Fan; Tanabe, Tadashi; McCaffrey, Timothy A.; Dannenberg, Andrew J.; Weksler, Babette B.

CS Departments of Medicine, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY, 10021, USA

SO Journal of Biological Chemistry (2000), 275(7), 4949-4955
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 87 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:799633 CAPLUS

DN 132:92136

TI Oncostatin M induces interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells: synergy with interleukin-1 β .

AU Bernard, Catherine; Merval, Regine; Lebrete, Marilyne; Delerive, Philippe; Dusanter-Fourt, Isabelle; Lehoux, Stephanie; Creminon, Christophe; Staels, Bart; Macclouf, Jacques; Tedgui, Alain

CS Institut National de la Sante et de la Recherche Medicale U141, Paris, 75475, Fr.

SO Circulation Research (1999), 85(12), 1124-1131
CODEN: CIRUAL; ISSN: 0009-7330

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 88 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:711559 CAPLUS
DN 132:192648
TI Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions
AU Schonbeck, Uwe; Shkova, Galina K.; Graber, Pierre; Coulter, Stephanie;
Libby, Peter
CS Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division,
Department of Medicine, Harvard Medical School, Brigham and Women's
Hospital, Boston, MA, 02115, USA
SO American Journal of Pathology (1999), 155(4), 1281-1291
CODEN: AJPAA4; ISSN: 0002-9440
PB American Society for Investigative Pathology
DT Journal
LA English

RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 89 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:489699 CAPLUS
DN 131:269975
TI Oxidized low density lipoprotein suppresses expression of inducible
cyclooxygenase in human macrophages
AU Eligini, Sonia; Colli, Susanna; Basso, Federica; Sironi, Luigi; Tremoli,
Elena
CS E. Grossi Paoletti Center, Institute of Pharmacological Sciences,
University of Milan, Milan, 20133, Italy
SO Arteriosclerosis, Thrombosis, and Vascular Biology (1999), 19(7),
1719-1725
CODEN: ATVBFA; ISSN: 1079-5642
PB Lippincott Williams & Wilkins
DT Journal
LA English

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 90 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:307009 CAPLUS
DN 131:142865
TI Vascular endothelial genes that are responsive to tumor necrosis
factor- α . in vitro are expressed in atherosclerotic lesions,
including inhibitor of apoptosis protein-1, stannin, and two novel genes
AU Horrevoets, Anton J. G.; Fontijn, Ruud D.; Van Zonneveld, Anton Jan; De
Vries, Carlisle J. M.; ten Cate, Jan Wouter; Pannekoek, Hans
CS Department of Biochemistry and Vascular Medicine of the Academic Medical
Center, University of Amsterdam, Amsterdam, 1105 AZ, Neth.
SO Blood (1999), 93(10), 3418-3431
CODEN: BLOOAW; ISSN: 0006-4971
PB W. B. Saunders Co.
DT Journal
LA English

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 91 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:282039 CAPLUS
DN 130:306593
TI Combination therapy using a HMG-CoA reductase inhibitor and a
cyclooxygenase-2 (COX-2) inhibitor for reducing the
risks associated with cardio- and cerebrovascular disease

IN Winokur, Melvin
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9920110	A1	19990429	WO 1998-US21901	19981016
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2306646	AA	19990429	CA 1998-2306646	19981016
	AU 9913612	A1	19990510	AU 1999-13612	19981016
	AU 753657	B2	20021024		
	EP 1024696	A1	20000809	EP 1998-957328	19981016
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	JP 2001520174	T2	20011030	JP 2000-516533	19981016
	US 6245797	B1	20010612	US 1998-179349	19981020
PRAI	US 1997-62691P	P	19971022		
	GB 1998-6688	A	19980327		
	WO 1998-US21901	W	19981016		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE.FORMAT

L15 ANSWER 92 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:272886 CAPLUS
DN 131:114680
TI High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2
AU Cockerill, Gillian W.; Saklatvala, Jeremy; Ridley, Simon H.; Yarwood, Helen; Miller, Norman E.; Oral, Barbaros; Nithyanathan, Saro; Taylor, Graham; Haskard, Dorian O.
CS BHF Cardiovascular Medicine Unit, St Bartholomews and the Royal School of Medicine and Dentistry, London, UK
SO Arteriosclerosis, Thrombosis, and Vascular Biology (1999), 19(4), 910-917
CODEN: ATVBFA; ISSN: 1079-5642
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE.FORMAT

L15 ANSWER 93 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:215430 CAPLUS
DN 131:42987
TI Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
AU Baker, Christopher S. R.; Hall, Roger J. C.; Evans, Thomas J.; Pomerance, Ariela; Macclouf, Jacques; Creminon, Christophe; Yacoub, Magdi H.; Polak, Julia M.
CS Department of Cardiology, Imperial College School of Medicine, Harefield Hospital Campus, London, UK
SO Arteriosclerosis, Thrombosis, and Vascular Biology (1999), 19(3), 646-655

CODEN: ATVBFA; ISSN: 1079-5642

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 94 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:55922 CAPLUS

DN 130:250270

TI iNOS and COX-2 in atherosclerosis

AU Buttery, Lee D. K.; Polak, Julia M.

CS Department of Histochemistry, Imperial College School of Medicine, London,
W12 0NN, UK

SO Inducible Enzymes in the Inflammatory Response (1999), 109-124.

Editor(s): Willoughby, Derek A.; Tomlinson, Annette. Publisher:

Birkhaeuser, Basel, Switz.

CODEN: 67FLAD

DT Conference; General Review

LA English

RE.CNT 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 95 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:539097 CAPLUS

DN 129:300613

TI Vascular endothelium, hemodynamic forces and atherogenesis

AU Gimbrone, Michael A., Jr.; Topper, James N.

CS Vascular Research Division, Departments of Pathology, Harvard Medical
School, Boston, MA, USA

SO International Congress Series (1998), 1155(Atherosclerosis XI), 949-955

CODEN: EXMDA4; ISSN: 0531-5131

PB Elsevier Science B.V.

DT Journal; General Review

LA English

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 96 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:492501 CAPLUS

DN 129:211298

TI Aspirin attenuates cytomegalovirus infectivity and gene expression
mediated by cyclooxygenase-2 in coronary artery smooth muscle cells

AU Speir, Edith; Yu, Zu-Xi; Ferrans, Victor J.; Huang, Eng-Shang; Epstein,
Stephen E.

CS Cardiology Branch, National Heart, Lung, and Blood Institute (NHLBI),
National Institutes of Health (NIH), Bethesda, MD, 20892-1650, USA

SO Circulation Research (1998), 83(2), 210-216

CODEN: CIRUAL; ISSN: 0009-7330

PB Williams & Wilkins

DT Journal

LA English

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 97 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:421446 CAPLUS

DN 129:131248

TI NF-.kappa.B activation inhibitors containing lignans and their uses

IN Murase, Takatoshi; Hase, Tadashi; Tokimitsu, Ichiro

PA Kao Corp., Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10175861	A2	19980630	JP 1996-335396	19961216
PRAI	JP 1996-335396		19961216		
OS	MARPAT 129:131248				

L15 ANSWER 98 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:394334 CAPLUS

DN 129:67791

TI Preparation of 2-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidines and related compounds as drugs

IN Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.

PA Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.

SO PCT Int. Appl., 232 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9824782	A2	19980611	WO 1997-US22390	19971204
	WO 9824782	A3	19980827		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9710727	A	19980612	ZA 1997-10727	19971128
	AU 9860120	A1	19980629	AU 1998-60120	19971204
	AU 733877	B2	20010531		
	EP 948497	A2	19991013	EP 1997-954778	19971204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9713850	A	20000229	BR 1997-13850	19971204
	CN 1246858	A	20000308	CN 1997-181563	19971204
	NZ 335997	A	20010831	NZ 1997-335997	19971204
	JP 2002514195	T2	20020514	JP 1998-525850	19971204
	EP 1314731	A2	20030528	EP 2002-27704	19971204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, MK, AL				
	EP 1314732	A2	20030528	EP 2002-27705	19971204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
	ZA 9710911	A	19980605	ZA 1997-10911	19971205
	MX 9905168	A	20000228	MX 1999-5168	19990603
	US 6410729	B1	20020625	US 2000-598740	20000621
	US 2003069425	A1	20030410	US 2002-117552	20020403
PRAI	US 1996-32128P	P	19961205		
	US 1997-50950P	P	19970613		
	US 1997-976054	A	19971121		
	EP 1997-954778	A3	19971204		
	US 1997-984774	B1	19971204		
	WO 1997-US22390	W	19971204		
	US 2000-598740	A3	20000621		
OS	MARPAT 129:67791				

L15 ANSWER 99 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:409644 CAPLUS
 DN 127:76459
 TI Antimitotic actions of vasodilatory prostaglandins - clinical aspects
 AU Sinzinger, H.; Fitscha, P.; Kritz, H.
 CS Wilhelm Auerswald Atherosclerosis Research Group (ASF), Vienna, A-1090, Austria
 SO Agents and Actions Supplements (1997), 48(Prostaglandins and Control of Vascular Smooth Muscle Cell Proliferation), 92-106
 CODEN: AASUDJ; ISSN: 0379-0363
 PB Birkhaeuser
 DT Journal
 LA English

L15 ANSWER 100 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:406617 CAPLUS
 DN 127:134640
 TI Monocytic-endothelial cell interaction: regulation of prostanoid synthesis in human coculture
 AU Koll, Sylvia; Goppelt-Struebe, Margarete; Hauser, Ingeborg; Goerig, Matthias
 CS Dep. Internal Med. IV, Med. Sch. Res. Labs., Univ. Erlangen-Nuernberg, Erlangen, D-91054, Germany
 SO Journal of Leukocyte Biology (1997), 61(6), 679-688
 CODEN: JLBIE7; ISSN: 0741-5400
 PB Federation of American Societies for Experimental Biology
 DT Journal
 LA English

L15 ANSWER 101 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:365560 CAPLUS
 DN 127:79348
 TI Urinary 8-Epi PGF2.alpha.: an index of oxidant stress in vivo
 AU Reilly, M. P.; Barry, P.; Lawson, J. A.; Fitzgerald, G.
 CS The Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, PA, 19104, USA
 SO Fibrinolysis & Proteolysis (1997), 11(Suppl. 1, Third International Fibrinogen Symposium: Hemostasis, Inflammation and Cardiovascular Disease, 1996), 81-84
 CODEN: FBPRFP
 PB Churchill Livingstone
 DT Journal; General Review
 LA English

L15 ANSWER 102 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:184589 CAPLUS
 DN 124:285056
 TI Oxidized Low-Density Lipoprotein Stimulates Protein Kinase C (PKC) and Induces Expression of PKC-Isotypes via Prostaglandin-H-Synthase in P388D1 Macrophage-Like Cells
 AU Claus, Ralf; Fyrnys, Beatrix; Deigner, Hans P.; Wolf, Gert
 CS Pharmazeutisch-Chemisches institut, Universitaet Heidelberg, Heidelberg, 69120, Germany
 SO Biochemistry (1996), 35(15), 4911-22
 CODEN: BICHAW; ISSN: 0006-2960
 PB American Chemical Society
 DT Journal
 LA English

L15 ANSWER 103 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:544537 CAPLUS

DN 122:282319
TI Regulatory mechanisms of the vascular endothelium: an update
AU Vane, John R.; Botting, Regina M.
CS Medical College, St. Bartholomew's Hospital, London, EC1M 6BQ, UK
SO Polish Journal of Pharmacology (1994), 46(6), 499-521
CODEN: PJPAE3; ISSN: 1230-6002
DT Journal; General Review
LA English

L15 ANSWER 104 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:6022 CAPLUS
DN 120:6022
TI Eicosanoid metabolism in cholesterol-enriched arterial smooth muscle cells. Evidence for reduced posttranscriptional processing of cyclooxygenase I and reduced cyclooxygenase II gene expression
AU Pomerantz, Kenneth B.; Summers, Barbara; Hajjar, David P.
CS Med. Coll., Cornell Univ., New York, NY, 10021, USA
SO Biochemistry (1993), 32(49), 13624-35
CODEN: BICHAW; ISSN: 0006-2960
DT Journal
LA English

=> d l15 94.all

L15 ANSWER 94 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:55922 CAPLUS
DN 130:250270
TI iNOS and **COX-2** in **atherosclerosis**
AU Buttery, Lee D. K.; Polak, Julia M.
CS Department of Histochemistry, Imperial College School of Medicine, London, W12 0NN, UK
SO Inducible Enzymes in the Inflammatory Response (1999), 109-124.
Editor(s): Willoughby, Derek A.; Tomlinson, Annette. Publisher: Birkhaeuser, Basel, Switz.
CODEN: 67FLAD
DT Conference; General Review
LA English
CC 14-0 (Mammalian Pathological Biochemistry)
AB A review, with 80 refs., discusses the actions of mediators, e.g., prostacyclin and nitric oxide, in **atherosclerosis**, focusing on the enzymes regulating their synthesis, esp. their inducible isoforms.
ST review **atherosclerosis** NO synthase cyclooxygenase 2
IT **Atherosclerosis**
(inducible NO synthase and cyclooxygenase-2 in **atherosclerosis**)
IT 39391-18-9, Cyclooxygenase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(2; inducible NO synthase and cyclooxygenase-2 in **atherosclerosis**)
IT 10102-43-9, Nitric oxide, biological studies 35121-78-9, Prostacyclin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(inducible NO synthase and cyclooxygenase-2 in **atherosclerosis**)
IT 125978-95-2, NO synthase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(inducible; inducible NO synthase and cyclooxygenase-2 in **atherosclerosis**)

RE.CNT 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Asada, Y; Prostaglandin Leukot Essent Fatty Acids 1994, V51, P245 CAPLUS
- (2) Baker, C; Arterioscler Thromb Vasc Biol; in press 1998
- (3) Beckman, J; Biol Chem-Hoppe Seyer 1994, V375, P81
- (4) Braun, M; Agents and Actions 1992, V37, P282 CAPLUS
- (5) Brown, M; Ann Rev Biochem 1983, V52, P223 CAPLUS
- (6) Bunting, S; Prostaglandins 1976, V12, P897 CAPLUS
- (7) Buttery, L; Curr Diag Path 1995, V2, P111
- (8) Buttery, L; J Path 1996, V179, P197 MEDLINE
- (9) Buttery, L; Lab Invest 1996, V75, P76
- (10) Celermajer, D; N Eng J Med 1996, V334, P150 CAPLUS
- (11) Chester, A; Lancet 1991, V336, P897
- (12) Cooke, J; Circulation 1991, V83, P1057 CAPLUS
- (13) Crow, J; Adv Pharmacol 1995, V34, P17 CAPLUS
- (14) Crutchley, D; J Pharm Exp Therap 1982, V222, P544 CAPLUS
- (15) Darley-Usmar, V; Free Rad Res Comm 1992, V17, P19
- (16) Dembinska-Kiec, A; Prostaglandins 1977, V14, P1025 CAPLUS
- (17) Dembinska-Kiec, A; Thromb Haemost 1982, V47, P90
- (18) Douglas, S; Eur J Pharmacol 1994, V255, P81 CAPLUS
- (19) Drexler, H; Lancet 1991, V338, P1546 MEDLINE
- (20) D'Angelo, V; Thromb Haemostasis 1978, V39, P535 CAPLUS
- (21) Fitzgerald, G; N Eng J Med 1984, V310, P1065 CAPLUS
- (22) Forstermann, U; Circ Res 1988, V62, P185 MEDLINE
- (23) Freeman, B; Chest 1994, V105(Suppl), P79S
- (24) Garg, U; J Clin Invest 1989, V83, P1774 CAPLUS
- (25) Gow, A; FEBS Lett 1996, V385, P63 CAPLUS
- (26) Graham, A; FEBS Lett 1993, V330, P181 CAPLUS
- (27) Gross, S; Ann Rev Physiol 1995, V57, P737 CAPLUS
- (28) Gruentzig, A; Circulation 1977, V84(Suppl2), PII55
- (29) Haddad, I; J Clin Invest 1994, V94, P2407 CAPLUS
- (30) Hajjar, D; J Am Chem Soc 1995, V117, P3340 CAPLUS
- (31) Hogg, N; FEBS Lett 1993, V334, P170 CAPLUS
- (32) Hughes, F; J Biol Chem; in press 1998
- (33) Kadish, J; Med Hypoth 1995, V45, P205 CAPLUS
- (34) Kaur, H; FEBS Lett 1994, V350, P9 CAPLUS
- (35) Kawabata, A; Br J Pharmacol 1996, V117, P236 CAPLUS
- (36) Keaney, J; Progress in Cardiovasc Dis 1995, V33, P129
- (37) Khan, B; PNAS 1996, V93, P9114 CAPLUS
- (38) Knowles, R; Biochem J 1995, V298, P249
- (39) Kubes, P; PNAS 1991, V88, P4651 CAPLUS
- (40) Levy, R; N Eng J Med 1981, V305, P399 MEDLINE
- (41) Liao, J; J Biol Chem 1995, V270, P391
- (42) Libby, P; Lab Invest 1991, V64, P5 MEDLINE
- (43) Loskove, J; Am Heart J 1995, V129, P604 MEDLINE
- (44) Lynch, S; J Clin Invest 1994, V93, P998 CAPLUS
- (45) Milano, S; Prostaglandins 1995, V49, P105 CAPLUS
- (46) Mitchell, J; Biochem Pharmacol 1995, V50, P1535 CAPLUS
- (47) Mitchinson, M; Lancet 1987, V2, P146 MEDLINE
- (48) Moncada, S; Nature 1976, V263, P663 CAPLUS
- (49) Moncada, S; Pharmacol Rev 1979, V30, P293
- (50) Moore, K; Circ Res 1995, V77, P335 CAPLUS
- (51) Moro, M; PNAS 1994, V91, P6702 CAPLUS
- (52) Mugge, A; Circ Res 1991, V69, P1293 CAPLUS
- (53) Nabel, E; Science 1989, V244, P1342 MEDLINE
- (54) Nobuyoshi, M; J Am Coll Cardiol 1991, V17, P433 MEDLINE
- (55) Nussler, A; J Leuko Biol 1993, V54, P171 CAPLUS
- (56) O'Brien, K; Med Clin North Am 1994, V78, P41 CAPLUS
- (57) Palmer, R; Nature 1987, V327, P524 CAPLUS
- (58) Radomski, M; Br J Pharmacol 1987, V92, P639 CAPLUS
- (59) Radomski, M; Lancet 1987, V2, P1057 MEDLINE
- (60) Ross, R; Am J Path 1993, V143, P987 MEDLINE

- (61) Ross, R; N Eng J Med 1976, V295, P369 MEDLINE
- (62) Ross, R; N Eng J Med 1986, V314, P488 MEDLINE
- (63) Salvemini, D; J Clin Invest 1996, V97, P2562 CAPLUS
- (64) Salvemini, D; Met Enzymol 1996, V269, P12 CAPLUS
- (65) Salvemini, D; PNAS 1993, V90, P7240 CAPLUS
- (66) Schini, V; Am J Physiol 1993, V264, PH611 CAPLUS
- (67) Schini, V; Eur J Pharmacol 1992, V216, P379 CAPLUS
- (68) Shears, L; J Clin Invest 1997, V100, P2035 CAPLUS
- (69) Sinzinger, H; J Physiol Pharmacol 1994, V45, P27
- (70) Steering Committee Of The Physician'S Health Study Research Group; N Eng J Med 1989, V321, P129
- (71) Szczeklik, A; Thromb Res 1983, V29, P655 CAPLUS
- (72) Topper, J; PNAS 1996, V93, P10417 CAPLUS
- (73) Tremoli, E; Prostaglandins 1982, V24, P397 CAPLUS
- (74) Tzeng, E; Curr Probl Surg 1996, V33, P961 MEDLINE
- (75) Von der Leyen, H; PNAS 1995, V92, P1137 CAPLUS
- (76) White, C; PNAS 1994, V91, P1044 CAPLUS
- (77) Wilcox, J; J Am Coll Cardiol 1993, V72, P88E MEDLINE
- (78) Wu, K; Adv Pharmacol 1995, V33, P179 CAPLUS
- (79) Zembowicz, A; J Clin Invest 1995, V96, P1688 CAPLUS
- (80) Zou, M; Biol Chem 1997, V378, P707 CAPLUS

=> d 115 91 all

L15 ANSWER 91 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:282039 CAPLUS
 DN 130:306593
 TI Combination therapy using a HMG-CoA reductase inhibitor and a
 cyclooxygenase-2 (COX-2) inhibitor for reducing the
 risks associated with cardio- and cerebrovascular disease
 IN Winokur, Melvin
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A01N043-16
 ICS A01N043-40
 CC 1-8 (Pharmacology)
 Section cross-reference(s): 28, 63
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9920110	A1	19990429	WO 1998-US21901	19981016
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2306646	AA	19990429	CA 1998-2306646	19981016
	AU 9913612	A1	19990510	AU 1999-13612	19981016
	AU 753657	B2	20021024		
	EP 1024696	A1	20000809	EP 1998-957328	19981016
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	JP 2001520174	T2	20011030	JP 2000-516533	19981016
	US 6245797	B1	20010612	US 1998-179349	19981020
PRAI	US 1997-62691P	P	19971022		
	GB 1998-6688	A	19980327		

- AB The invention provides a drug combination comprised of a HMG-CoA reductase inhibitor in combination with a **COX-2** inhibitor, which is useful for treating, preventing, and/or reducing the risk of developing **atherosclerosis** and atherosclerotic disease events. Prepn. of selected **COX-2** inhibitors, e.g. 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, is described. Pharmaceutical formulations are included.
- ST COX2 inhibitor prepn cardiovascular drug combination; HMG CoA reductase inhibitor cardiovascular combination
- IT Anti-ischemic agents
Cardiovascular agents
Drug delivery systems
Platelet aggregation inhibitors
(HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)
- IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LDL, inducers; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)
- IT Antiarteriosclerotics
(antiatherosclerotics; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)
- IT Sequestering agents
(bile acid; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)
- IT Drug delivery systems
(capsules; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)
- IT Brain, disease
(cerebrovascular; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)
- IT Heart
(coronary revascularization procedures; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)
- IT Artery, disease
(coronary; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)
- IT Cardiovascular system
(disease; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)
- IT Death
(from coronary heart disease; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd.

with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Heart, disease
(infarction; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Drug delivery systems
(infusions, i.v.; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Artery, disease
(intermittent claudication; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Brain, disease
(ischemia, transient; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Blood vessel, disease
(peripheral; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Bile acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(sequestrants; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Drug delivery systems
(solns., oral; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Brain, disease
(stroke; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Drug delivery systems
(suspensions, oral; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Drug delivery systems
(tablets; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT Adrenoceptor antagonists
(.beta.-; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT 39391-18-9
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and

cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT 202409-30-1P 202409-31-2P 202409-33-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT 50-81-7, Vitamin C, biological studies 59-30-3, Folic acid, biological studies 59-30-3D, Folic acid, esters 59-67-6, Niacin, biological studies 68-19-9, Vitamin B12 943-45-3D, Fibric acid, derivs. 1406-18-4, Vitamin E 7235-40-7, .beta.-Carotene 8059-24-3, Vitamin B6 23288-49-5, Probucol 75330-75-5, Lovastatin 75330-75-5D, Lovastatin, esters and lactones 79902-63-9, Simvastatin 79902-63-9D, Simvastatin, esters and lactones 81093-37-0, Pravastatin 81093-37-0D, Pravastatin, esters and lactones 93957-54-1, Fluvastatin 93957-54-1D, Fluvastatin, esters and lactones 134523-00-5, Atorvastatin 134523-00-5D, Atorvastatin, esters and lactones 145599-86-6, Cerivastatin 145599-86-6D, Cerivastatin, esters and lactones 162011-83-8 162011-90-7 178402-36-3 185147-73-3 189954-66-3 189954-93-6 189954-96-9 189956-36-3 190966-03-1 190966-25-7 190966-32-6 212126-32-4 223663-01-2 223663-03-4 223663-06-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT 9028-35-7, HMG-CoA reductase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT 57-88-5, Cholest-5-en-3-ol (3.beta.)-, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (absorption, inhibitors; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT 9027-44-5, HMG-CoA synthase 9027-63-8, Acyl coenzyme A-cholesterol acyltransferase 9029-62-3, Squalene epoxidase 9077-14-9, Squalene synthetase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT 111770-91-3P 137628-16-1P 175883-59-7P 202409-79-8P 202409-82-3P 202409-84-5P 202409-85-6P 202409-86-7P 202409-87-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reaction; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

IT 100-39-0, Benzyl bromide 109-04-6, 2-Bromopyridine 109-72-8, n-Butyllithium, reactions 358-23-6, Trifluoromethanesulfonic acid anhydride 626-55-1, 3-Bromopyridine 661-69-8, Hexamethylditin

1121-78-4, 5-Hydroxy-2-methylpyridine 4214-79-3, 5-Chloro-2-hydroxypyridine 5419-55-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; HMG-CoA reductase inhibitor combination with **COX-2** inhibitor for reducing risks assocd. with cardio- and cerebrovascular disease, **COX-2** inhibitor prepn., and pharmaceutical formulations)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Pallenberg; WO 9639144 A1 Database HCAPLUS on STN 1996 CAPLUS

=> d 115 85 all

L15 ANSWER 85 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:183592 CAPLUS
DN 132:320769
TI Release of GM-CSF and G-CSF by human arterial and venous smooth muscle cells: differential regulation by **COX-2**
AU Stanford, Salome J.; Pepper, John R.; Mitchell, Jane A.
CS Unit of Critical Care, Imperial College School of Medicine, The Royal Brompton and Harefield N.H.S. Trust, London, SW3 6NP, UK
SO British Journal of Pharmacology (2000), 129(5), 835-838
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
CC 15-5 (Immunochemistry)
Section cross-reference(s): 14
AB In addn. to their traditional contractile function, vascular smooth muscle cells can be stimulated under inflammatory conditions to release a range of potent biol. mediators. Indeed, the authors and others have shown that human vascular smooth muscle release the colony stimulating factors (CSF) granulocyte macrophage-CSF (GM-CSF) and granulocyte-CSF (G-CSF) as well as large amts. of prostaglandins following the induction of cyclo-oxygenase-2 (**COX-2**), when stimulated with cytokines. Here the authors demonstrate, for the first time, that co-induced **COX-2** activity simultaneously suppresses GM-CSF release and potentiates G-CSF release by human vascular cells. Moreover, the differential regulation of GM-CSF and G-CSF release by **COX-2** was mimicked by the prostacyclin (PGI2) mimetic, cicaprost. Thus, PGI2, released following the induction of **COX-2**, differentially regulates the release of GM-CSF (suppresses) and G-CSF (potentiates) from human vascular cells.
ST GMCSF GCSF artery vein smooth muscle COX2 cyclooxygenase
atherosclerosis
IT Artery
Atherosclerosis
Vein
(PGI2 released following cyclooxygenase-2 induction differentially regulates release of GM-CSF and G-CSF by human vascular cells)
IT Blood vessel
(smooth muscle; PGI2 released following cyclooxygenase-2 induction differentially regulates release of GM-CSF and G-CSF by human vascular cells)
IT 39391-18-9
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(2; PGI2 released following cyclooxygenase-2 induction differentially regulates release of GM-CSF and G-CSF by human vascular cells)
IT 35121-78-9, PGI2

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)

(PGI2 released following cyclooxygenase-2 induction differentially regulates release of GM-CSF and G-CSF by human vascular cells)

IT 83869-56-1, GM-CSF 143011-72-7, Granulocyte colony-stimulating factor
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)

(PGI2 released following cyclooxygenase-2 induction differentially regulates release of GM-CSF and G-CSF by human vascular cells)

RE: CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Agro, A; J Rheumatol 1996, V23, P862 CAPLUS
- (2) Bishop-Bailey, D; Arterioscler Thromb Vasc Biol 1998, V18, P1655 CAPLUS
- (3) Colotta, F; Blood 1992, V80, P2012 CAPLUS
- (4) Eischen, A; J Immunol Methods 1991, V143, P209 CAPLUS
- (5) Erickson-Miller, C; Int J Cell Cloning 1990, V8, P346 MEDLINE
- (6) Hamilton, J; Blood 1992, V79, P1413 CAPLUS
- (7) Lee, M; J Leuk Biol 1990, V47, P275 CAPLUS
- (8) Lopez, A; J Clin Invest 1986, V78, P1220 CAPLUS
- (9) Luttmann, W; Pulm Pharmacol 1996, V9, P43 CAPLUS
- (10) Metcalf, D; Blood 1986, V67, P257 CAPLUS
- (11) Mitchell, J; Br J Pharmacol 1999, V128, P1121 CAPLUS
- (12) Mitchell, J; Proc Natl Acad Sci USA 1993, V90, P11693 CAPLUS
- (13) Stanford, S; Arterioscler Thromb Vasc Biol in press 2000
- (14) Warner, T; Proc Natl Acad Sci USA 1999, V96, P7563 CAPLUS
- (15) Zoellner, H; Blood 1992, V80, P2805 CAPLUS

=> d 115 82 all

L15 ANSWER 82 OF 104 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:450705 CAPLUS

DN 133:320212

TI Endothelial dysfunction, hemodynamic forces, and atherogenesis

AU Gimbrone, Michael A., Jr.; Topper, James N.; Nagel, Tobi; Anderson, Keith R.; Garcia-Cardena, Guillermo

CS Vascular Research Division, Brigham and Women's Hospital, Boston, MA, 02115-5817, USA

SO Annals of the New York Academy of Sciences (2000), 902 (Atherosclerosis V, The Fifth Sarasota International Conference, 1999), 230-240
CODEN: ANYAA9; ISSN: 0077-8923

PB New York Academy of Sciences

DT Journal; General Review

LA English

CC 14-0 (Mammalian Pathological Biochemistry)

AB A review with 48 refs., with added discussion. Phenotypic modulation of endothelium to a dysfunctional state contributes to the pathogenesis of cardiovascular diseases such as **atherosclerosis**. The localization of atherosclerotic lesions to arterial geometries assocd. with disturbed flow patterns suggests an important role for local hemodynamic forces in atherogenesis. There is increasing evidence that the vascular endothelium, which is directly exposed to various fluid mech. forces generated by pulsatile blood flow, can discriminate among these stimuli and transduce them into genetic regulatory events. At the level of individual genes, this regulation is accomplished via the binding of certain transcription factors, such as NF.kappa.B and Egr-1, to shear-stress response elements (SSREs) that are present in the promoters of biomechanically inducible genes. At the level of multiple genes, distinct patterns of up- and downregulation appear to be elicited by exposure to steady laminar shear stresses vs. comparable levels of non-laminar (e.g., turbulent) shear stresses or cytokine stimulation

(e.g., IL-1.beta.). Certain genes upregulated by steady laminar shear stress stimulation (such as eNOS, **COX-2**, and Mn-SOD) support vasoprotective (i.e., antiinflammatory, antithrombotic, antioxidant) functions in the endothelium. The authors hypothesize that the selective and sustained expression of these and related "atheroprotective genes" in the endothelial lining of lesion-protected areas represents a mechanism whereby hemodynamic forces can influence lesion formation and progression.

ST review **atherosclerosis** vascular endothelium dysfunction gene expression; antioxidant gene expression vascular endothelium dysfunction **atherosclerosis** review; vasoprotectant gene expression vascular endothelium dysfunction **atherosclerosis** review; antithrombotic gene expression vascular endothelium dysfunction **atherosclerosis** review

IT Antioxidants
(antioxidants expression and endothelial dysfunction, hemodynamic forces, and atherogenesis)

IT Anticoagulants
(antithrombotics expression and endothelial dysfunction, hemodynamic forces, and atherogenesis)

IT Cytokines
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cytokines expression and endothelial dysfunction, hemodynamic forces, and atherogenesis)

IT Blood vessel, disease
(dysfunction; gene regulation in endothelial dysfunction, hemodynamic forces, and atherogenesis)

IT **Atherosclerosis**
Circulation
(gene regulation in endothelial dysfunction, hemodynamic forces, and atherogenesis)

IT Gene, animal
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gene regulation in endothelial dysfunction, hemodynamic forces, and atherogenesis)

IT Gene
(regulation; gene regulation in endothelial dysfunction, hemodynamic forces, and atherogenesis)

IT Transcription factors
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(transcription factor expression and endothelial dysfunction, hemodynamic forces, and atherogenesis)

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Bussolari, S; Rev Sci Instrum 1982, V53(12), P1851 MEDLINE
- (2) Caro, C; Proc Royal Soc London (B) 1971, V177, P109 CAPLUS
- (3) Chappell, D; Circ Res 1998, V82, P532 CAPLUS
- (4) Cornhill, J; Atherosclerosis 1976, V23, P489 MEDLINE
- (5) Davies, P; J Biomech 1995, V28, P1553 MEDLINE
- (6) Davies, P; Physiol Rev 1995, V75, P519 CAPLUS
- (7) Davies, P; Proc Natl Acad Sci USA 1986, V83, P2114 MEDLINE
- (8) Depaola, N; Arterioscler Thromb 1992, V12, P1254 MEDLINE
- (9) Depaola, N; Proc Natl Acad Sci USA 1996, V93, P3154 CAPLUS
- (10) Dewey, C; J Biomech Eng 1981, V103, P177
- (11) Dimmeler, S; FEBS Lett 1996, V399, P71 CAPLUS
- (12) Frangos, J; Jpn J Pharmacol 1997, V75, P31

- (13) Friedman, M; Circ Res 1975, V36, P277 MEDLINE
- (14) Gabriels, J; Circ Res 1998, V83, P636 CAPLUS
- (15) Garcia-Cardena, G; Ann N Y Acad Sci 2000
- (16) Giddens, D; J Biomech Eng 1993, V115, P588 MEDLINE
- (17) Gimbrone, M; Ann N Y Acad Sci 1997, V811, P1 CAPLUS
- (18) Gimbrone, M; Endothelium and Mechanical Forces 1999, PVII
- (19) Gimbrone, M; J Clin Invest 1997, V99(8), P1809 CAPLUS
- (20) Gimbrone, M; Molecular Basis of Heart Diseases 1998, P331
- (21) Glagov, S; Arch Pathol Lab Med 1988, V112, P1018 MEDLINE
- (22) Hsieh, J; J Cell Physiol 1993, V154, P143
- (23) Joris, I; acute aortic stenosis 1982, V106, P394 MEDLINE
- (24) Karino, T; Int Angiol 1986, V5, P297 MEDLINE
- (25) Khachigian, L; Arterioscler Thromb Vasc Biol 1997, V17, P2280 CAPLUS
- (26) Khachigian, L; J Clin Invest 1995, V96(2), P1169 CAPLUS
- (27) Korenaga, R; Am J Physiol 1997, V273, PC1506 CAPLUS
- (28) Langille, B; Science 1986, V231, P405 MEDLINE
- (29) Lin, M; J Clin Invest 1997, V15, P737
- (30) Malek, A; J Hypertens 1994, V12, P989 CAPLUS
- (31) Nagel, T; Arterioscler Thromb Vasc Biol In press 1999
- (32) Nakashima, Y; Arterioscler Thromb Vasc Biol 1994, V14, P133 CAPLUS
- (33) Nerem, R; J Biochem Eng 1981, V103, P172 MEDLINE
- (34) Pathobiological Determinants Of Atherosclerosis In Youth Pday Research Group; Arterioscler Thromb Vasc Biol 1993, V13, P1291
- (35) Remuzzi, A; Biorheology 1984, V21, P617 MEDLINE
- (36) Resnick, N; FASEB J 1995, V9, P874 CAPLUS
- (37) Resnick, N; Proc Natl Acad Sci USA 1993, V90, P4591 CAPLUS
- (38) Ross, R; N Engl J Med 1999, V340(2), P115 MEDLINE
- (39) Shyy, J; Proc Natl Acad Sci USA 1995, V92, P8069 CAPLUS
- (40) Tardy, Y; Arterio Thromb Vasc Biol 1997, V17, P3102 MEDLINE
- (41) Topper, J; Endothelium and Mechanical Forces 1999, P207 CAPLUS
- (42) Topper, J; Molec Med Today 1999, V5(1), P40 CAPLUS
- (43) Topper, J; Proc Natl Acad Sci USA 1996, V93, P10417 CAPLUS
- (44) Traub, O; Arterioscler Thromb Vasc Biol 1998, V18, P677 MEDLINE
- (45) Virchow, R; Wien Med Wochenshr 1856, V6, P825
- (46) Walpole, P; Arterioscler Thromb Vasc Biol 1995, V15, P2 CAPLUS
- (47) Wolf, N; Pathology of Atherosclerosis, Ch 9 1982, P187
- (48) Zand, T; Amer J Pathol 1999, V155(1), P85 MEDLINE

=>

=> s 15 and 113

10725 L2

L16 54 L5 AND L13

=> d 116 40-54

L16 ANSWER 40 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:592541 CAPLUS

DN 133:183011

TI Formulation of 5-HT agonists with COX-2 inhibitors

IN Plachetka, John R.

PA Pozen Inc., USA

SO PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000048583	A2	20000824	WO 2000-US3897	20000216
	WO 2000048583	A3	20001207		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-253278 A 19990219

L16 ANSWER 41 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:590899 CAPLUS
 DN 133:305529
 TI Effects of caffeine and paracetamol alone or in combination with
 acetylsalicylic acid on prostaglandin E2 synthesis in rat microglial cells
 AU Fiebich, B. L.; Lieb, K.; Hull, M.; Aicher, B.; van Ryn, J.; Pairet, M.;
 Engelhardt, G.
 CS Hauptstr. 5, Department of Psychiatry, University of Freiburg Medical
 School, Freiburg, D-79104, Germany
 SO Neuropharmacology (2000), 39(11), 2205-2213
 CODEN: NEPHBW; ISSN: 0028-3908
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 42 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:351391 CAPLUS
 DN 133:9109
 TI COX-2 inhibitors in combination with NMDA blockers for
 treating pain
 IN Caruso, Frank S.
 PA Algos Pharmaceutical Corporation, USA
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000029023	A1	20000525	WO 1998-US24317	19981112
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9914086	A1	20000605	AU 1999-14086	19981112
EP 1146905	A1	20011024	EP 1998-957950	19981112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002538078	T2	20021112	JP 2000-582069	19981112
PRAI WO 1998-US24317	A	19981112		
RE.CNT 2				
THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L16 ANSWER 43 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:351390 CAPLUS
 DN 132:343345

TI Cyclooxygenase 2 (COX-2) inhibitors in combination
with centrally acting analgesics for alleviation of pain
IN Caruso, Frank S.
PA Algos Pharmaceutical Corporation, USA
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000029022	A1	20000525	WO 1998-US24045	19981112
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9913988	A1	20000605	AU 1999-13988	19981112
PRAI	WO 1998-US24045	A	19981112		
RE.CNT	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L16 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:291005 CAPLUS
DN 132:321867
TI Preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors
IN Black, Lawrence A.; Basha, Anwer; Kolasa, Teodozyj; Kort, Michael E.; Liu, Huaqing; Mccarty, Catherine M.; Patel, Meena V.; Rohde, Jeffrey J.; Coghlan, Michael J.; Stewart, Andrew O.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 477 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000024719	A1	20000504	WO 1999-US25234	19991027
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9965230	A1	20000515	AU 1999-65230	19991027
EP	1124804	A1	20010822	EP 1999-953259	19991027
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6307047	B1	20011023	US 1999-427768	19991027
	BR 9914858	A	20020205	BR 1999-14858	19991027
	JP 2003512292	T2	20030402	JP 2000-578289	19991027
	NO 2001002061	A	20010627	NO 2001-2061	20010426
	BG 105523	A	20011231	BG 2001-105523	20010519
PRAI	US 1998-179605	A	19981027		
	US 1999-261872	A	19990303		

US 1999-298490 A 19990423
US 1999-427768 A 19991027
US 1997-56733P P 19970822
US 1998-129570 B2 19980805
US 1998-137457 B2 19980820
WO 1999-US25234 W 19991027

OS MARPAT 132:321867

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 45 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:507933 CAPLUS

DN 131:266745

TI Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than
cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a
full in vitro analysis

AU Warner, Timothy D.; Giuliano, Francesco; Vojnovic, Ivana; Bukasa,
Antoaneta; Mitchell, Jane A.; Vane, John R.

CS The William Harvey Research Institute, St. Bartholomew's and the Royal
London School of Medicine and Dentistry, London, EC1M 6BQ, UK

SO Proceedings of the National Academy of Sciences of the United States of
America (1999), 96(13), 7563-7568
CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences

DT Journal

LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 46 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:438032 CAPLUS

DN 131:193920

TI Toxicity of human THP-1 monocytic cells towards neuron-like cells is
reduced by non-steroidal anti-inflammatory drugs (NSAIDs)

AU Klegeris, A.; Walker, D. G.; McGeer, P. L.

CS Kinsmen Laboratory of Neurological Research, University of British
Columbia, Vancouver, BC, V6T 1Z3, Can.

SO Neuropharmacology (1999), 38(7), 1017-1025
CODEN: NEPHBW; ISSN: 0028-3908

PB Elsevier Science Ltd.

DT Journal

LA English

RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 47 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:198781 CAPLUS

DN 131:395

TI Induction of an acetaminophen-sensitive cyclooxygenase with reduced
sensitivity to nonsteroid antiinflammatory drugs

AU Simmons, Daniel L.; Botting, Regina M.; Robertson, Philip M.; Madsen,
Matthew L.; Vane, John R.

CS Department of Chemistry and Biochemistry, Brigham Young University, Provo,
UT, 84602, USA

SO Proceedings of the National Academy of Sciences of the United States of
America (1999), 96(6), 3275-3280
CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences

DT Journal

LA English

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 48 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:166604 CAPLUS
 DN 130:223284
 TI Preparation of arylpyridazinones as prostaglandin endoperoxide H synthase biosynthesis inhibitors
 IN Black, Lawrence A.; Basha, Anwer; Kolasa, Teodozyj; Kort, Michael E.; Liu, Huaqing; McCarty, Catherine M.; Patel, Meena V.; Rohde, Jeffrey J.
 PA Abbott Laboratories, USA
 SO PCT Int. Appl., 307 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9910331	A1	19990304	WO 1998-US16479	19980810
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9886976	A1	19990316	AU 1998-86976	19980810
	AU 741317	B2	20011129		
	EP 1007515	A1	20000614	EP 1998-938451	19980810
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	BR 9812127	A	20000718	BR 1998-12127	19980810
	JP 2003516925	T2	20030520	JP 2000-507660	19980810
	ZA 9807555	A	19990223	ZA 1998-7555	19980820
	NO 2000000863	A	20000222	NO 2000-863	20000222
	MX 200001850	A	20001030	MX 2000-1850	20000222
	BG 104241	A	20001031	BG 2000-104241	20000315
PRAI	US 1997-917023	A	19970822		
	US 1998-129570	A	19980805		
	WO 1998-US16479	W	19980810		

OS MARPAT 130:223284

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:742265 CAPLUS
 DN 130:10645
 TI Cox-2 inhibitors in combination with NMDA blockers for treating pain
 IN Caruso, Frank S.
 PA Algos Pharmaceutical Corp., USA
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850075	A1	19981112	WO 1998-US9252	19980506
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				

UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9874727 A1 19981127 AU 1998-74727 19980506
PRAI US 1997-45914P P 19970507
WO 1998-US9252 W 19980506
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 50 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:400078 CAPLUS
DN 129:183979
TI Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used
nonsteroidal anti-inflammatory drugs
AU Cryer, Byron; Feldman, Mark
CS Department of Medicine, Dallas Department of Veterans Affairs Medical
Center and University of Texas Southwestern Medical School, Dallas, TX,
75216, USA
SO American Journal of Medicine (1998), 104(5), 413-421
CODEN: AJMEAZ; ISSN: 0002-9343
PB Excerpta Medica, Inc.
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 51 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:724792 CAPLUS
DN 128:43570
TI Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal
anti-inflammatory drugs (NSAIDs) and selective COX-2
inhibitors, using sensitive microsomal and platelet assays
AU Riendeau, Denis; Carleson, Stella; Cromlish, Wanda; Mancini, Joseph A.;
Wong, Elizabeth; Guay, Jocelyne
CS Merck Frosst Centre for Therapeutic Research, Kirkland, H9H 3L1, Can.
SO Canadian Journal of Physiology and Pharmacology (1997), 75(9), 1088-1095
CODEN: CJPPA3; ISSN: 0008-4212
PB National Research Council of Canada
DT Journal
LA English
RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 52 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:473623 CAPLUS
DN 125:158765
TI 8-Epi PGF2.alpha.: Specific analysis of an isoeicosanoid as an index of
oxidant stress in vivo
AU Delanty, N.; Reilly, M.; Pratico, D.; Fitzgerald, D. J.; Lawson, J. A.;
Fitzgerald, G. A.
CS Center Experimental Therapeutics, University Pennsylvania, Philadelphia,
PA, 19104, USA
SO British Journal of Clinical Pharmacology (1996), 42(1), 15-19
CODEN: BCPHBM; ISSN: 0306-5251
PB Blackwell
DT Journal
LA English

L16 ANSWER 53 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:736805 CAPLUS
DN 123:188000

TI Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and **Cox 2** inhibitors
 AU Grossman, C. J.; Wiseman, J.; Lucas, F. S.; Trevethick, M. A.; Birch, P. J.
 CS Molecular Science Department, Glaxo Research and Development, Hertfordshire, SG12 0DP, UK
 SO Inflammation Research (1995), 44(6), 253-7
 CODEN: INREFB; ISSN: 1023-3830
 PB Birkhaeuser
 DT Journal
 LA English

L16 ANSWER 54 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:69065 CAPLUS
 DN 120:69065
 TI Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
 AU Mitchell, Jane A.; Akarasereenont, Pravit; Thiemermann, Christoph; Flower, Roderick J.; Vane, John R.
 CS Med. Coll., St. Bartholomew's Hosp., London, EC1M 6BQ, UK
 SO Proceedings of the National Academy of Sciences of the United States of America (1993), 90(24), 11693-7
 CODEN: PNASA6; ISSN: 0027-8424
 DT Journal
 LA English

=> d 116 51 all

L16 ANSWER 51 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:724792 CAPLUS
 DN 128:43570
 TI Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective **COX-2** inhibitors, using sensitive microsomal and platelet assays
 AU Riendeau, Denis; Carleson, Stella; Cromlish, Wanda; Mancini, Joseph A.; Wong, Elizabeth; Guay, Jocelyne
 CS Merck Frosst Centre for Therapeutic Research, Kirkland, H9H 3L1, Can.
 SO Canadian Journal of Physiology and Pharmacology (1997), 75(9), 1088-1095
 CODEN: CJPPA3; ISSN: 0008-4212
 PB National Research Council of Canada
 DT Journal
 LA English
 CC 1-7 (Pharmacology)
 AB Two forms of cyclooxygenase (COX) activity are involved in the synthesis of prostaglandins, prostacyclins, and thromboxanes in mammalian cells. There is now convincing evidence, obtained with a no. of structurally distinct inhibitors, that selective **COX-2** inhibitors possess anti-inflammatory effects with an improved gastrointestinal tolerability compared with conventional nonsteroidal anti-inflammatory drugs (NSAIDs) affecting both COX-1 and **COX-2**. As more selective **COX-2** inhibitors are being developed, assays with a high degree of sensitivity to inhibition are needed to compared the relative effects of compds. on COX-1 activity. In the present report, we describe a sensitive assay for the inhibition of human COX-1 based on the prodn. of prostaglandin E2 by microsomes from U937 cells incubated with a subsaturating concn. of arachidonic acid. More than 45 NSAIDs and selective **COX-2** inhibitors were tested in this assay. IC50 values ranged from 1 nM for flunixin and flurbiprofen to about 200-500 .mu.M for salicylate and acetaminophen. Potent and nonselective NSAIDs such as sulindac sulfide, diclofenac, and

indomethacin showed IC50 values of <20 nM. Among the compds. that have been reported to show selectivity for **COX-2**, the rank order of potency against COX-1 was DuP 697 L > SC-58451 > celecoxib > nimesulfide .apprx. meloxicam .apprx. piroxicam .apprx. NS-398 .apprx. RS-57067 > SC-57666 > SC-58125 > flosulide > etodolac > L-745,337 > DFU .apprx. T-614, with IC50 values ranging from 7 nM to 17 .mu.M. A good correlation was obtained between the IC50 values for the inhibition of microsomal COX-1 and both the inhibition of TXB2 prodn. by Ca2+ ionophore challenged platelets and the inhibition of prostaglandin E2 prodn. by CHO cells stably expressing human COX-1. However, the microsomal assay was more sensitive to inhibition than cell-based assays and allowed the detection of inhibitory effects on COX-1 for all NSAIDs and selective **COX-2** inhibitors examd. with discrimination of their potency under conditions of limited availability of arachidonic acid.

ST NSAID cyclooxygenase inhibition test prostaglandin synthase
IT Anti-inflammatory agents
(nonsteroidal; comparison of cyclooxygenase-1 inhibitory properties of NSAIDs and selective **COX-2** inhibitors using sensitive microsomal and platelet assays)
IT 50-33-9, Phenylbutazone, biological studies 50-78-2, Acetylsalicylic acid 53-86-1, Indomethacin 61-68-7, Mefenamic acid 69-72-7, Salicylic acid, biological studies 103-90-2, Acetaminophen 530-78-9, Flufenamic acid 644-62-2, Meclofenamic acid 4394-00-7, Niflumic acid 5104-49-4, Flurbiprofen 13539-59-8, Azapropazone 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 22071-15-4, Ketoprofen 22204-53-1, Naproxen 23981-47-7 26171-23-3, Tolmetin 29679-58-1, Fenoprofen 33369-31-2, Zomepirac 34552-84-6, Isoxicam 34645-84-6, Fenclofenac 36322-90-4, Piroxicam 38194-50-2, Sulindac sulfoxide 38677-85-9, Flunixin 41340-25-4, Etodolac 42924-53-8, Nabumetone 49627-27-2, Sulindac sulfide 51234-28-7, Benoxaprofen 51543-39-6, (S)-Flurbiprofen 51543-40-9, (R)-Flurbiprofen 51803-78-2, Nimesulide 53716-49-7, Carprofen 59804-37-4, Tenoxicam 59973-80-7, Sulindac sulfone 66000-40-6, BW 755C 71125-38-7, Meloxicam 74103-06-3, Ketorolac 80937-31-1, Flosulide 88149-94-4, DuP 697 103475-41-8, Tepoxalin 120210-48-2, Tenidap 123653-11-2, NS-398 123663-49-0, T-614 158205-05-1, L 745337 158959-32-1, SC-57666 162054-19-5, SC-58125 168433-84-9, SC-58451 169590-42-5, Celecoxib 172324-19-5, L 745296 178402-36-3 179382-91-3, RS-57067
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparison of cyclooxygenase-1 inhibitory properties of NSAIDs and selective **COX-2** inhibitors using sensitive microsomal and platelet assays)
IT 363-24-6, Prostaglandin E2 39391-18-9 54397-85-2, TXB2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(comparison of cyclooxygenase-1 inhibitory properties of NSAIDs and selective **COX-2** inhibitors using sensitive microsomal and platelet assays)
IT 9055-65-6, Prostaglandin synthase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(comparison of cyclooxygenase-1 inhibitory properties of NSAIDs and selective **COX-2** inhibitors using sensitive microsomal and platelet assays)
RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Allison, M; New Engl J Med 1992, V327, P749 MEDLINE
(2) Appleyard, C; Am J Physiol 1996, V270, PG42 CAPLUS
(3) Argentieri, D; J Pharmacol Exp Ther 1994, V271, P1399 CAPLUS
(4) Bakhle, Y; Mediators Inflammation 1996, V5, P305 CAPLUS
(5) Barnett, J; EP 714895 1996 CAPLUS

- (6) Battistini, B; Drug News Perspect 1994, V7, P501
- (7) Bennett, A; Lancet 1995, V346, P1105 MEDLINE
- (8) Blower, P; J Rheumatol 1992, V19(Suppl 36), P13
- (9) Boughton-Smith, N; Br J Pharmacol 1983, V78, P173 CAPLUS
- (10) Champion, G; Drugs 1997, V53, P6 MEDLINE
- (11) Chan, C; Exp Ther 1995, V274, P1531 CAPLUS
- (12) Copeland, R; Proc Natl Acad Sci U S A 1994, V91, P11202 CAPLUS
- (13) Doyle, M; Prostaglandins 1989, V38, P581 CAPLUS
- (14) Ehrich, E; Arthritis Rheum 1996, V39(Suppl 9), PS81
- (15) Engelhardt, G; Biochem Pharmacol 1996, V51, P21 CAPLUS
- (16) Engelhardt, G; Inflamm Res 1995, V44, P423 CAPLUS
- (17) Futaki, N; Arch Int Pharmacodyn Ther 1992, V316, P114 CAPLUS
- (18) Futaki, N; Prostaglandins 1994, V47, P55 CAPLUS
- (19) Gans, K; J Pharmacol Exp Ther 1990, V254, P180 CAPLUS
- (20) Gierse, J; Biochem J 1995, V305, P479 CAPLUS
- (21) Griswold, D; Med Res Rev 1996, V16, P181 CAPLUS
- (22) Grossmann, C; Inflamm Res 1995, V44, P253
- (23) Hayllar, J; Lancet 1995, V346, P1629 MEDLINE
- (24) Herschman, H; Biochim Biophys Acta 1996, V1299, P125 CAPLUS
- (25) Hubbard, R; Arthritis Rheum 1996, V39(Suppl 9), PS226
- (26) Hudson, N; Hepatogastroenterol 1992, V39(Suppl 1), P31
- (27) Kargman, S; Biochem Pharmacol 1996, V52, P1113 CAPLUS
- (28) Kargman, S; Gastroenterology 1996, V111, P445 CAPLUS
- (29) Klein, T; Biochem Pharmacol 1994, V48, P1605 CAPLUS
- (30) Laneuville, O; J Pharmacol Exp Ther 1995, V271, P927
- (31) Langenbach, R; Cell 1995, V83, P483 CAPLUS
- (32) Langman, M; Lancet 1994, V343, P1075 MEDLINE
- (33) Laporte, J; Lancet 1991, V337, P85 MEDLINE
- (34) Leblanc, Y; Bioorg Med Chem Lett 1995, V5, P2123 CAPLUS
- (35) Masferrer, J; Proc Natl Acad Sci U S A 1994, V91, P3228 CAPLUS
- (36) Melarange, R; Inflammopharmacology 1995, V3, P259 CAPLUS
- (37) Moore, P; Inflamm Res 1996, V45, P54 CAPLUS
- (38) Ouellet, M; Biochem J 1995, V306, P247
- (39) O'Neill, G; Mol Pharmacol 1994, V45, P245 CAPLUS
- (40) Polisson, R; Am J Med 1996, V100, P31S CAPLUS
- (41) Preclik, G; Prostaglandins 1992, V44, P177 CAPLUS
- (42) Rainsford, K; Acta Physiol Hungarica 1992, V80, P23 CAPLUS
- (43) Reitz, D; Bioorg Med Chem Lett 1995, V5, P867 CAPLUS
- (44) Reitz, D; J Med Chem 1994, V37, P3878 CAPLUS
- (45) Riendeau, D; Br J Pharmacol 1997, V121, P105 CAPLUS
- (46) Seibert, K; Proc Natl Acad Sci U S A 1994, V91, P12013 CAPLUS
- (47) Tanaka, K; Jpn J Pharmacol 1995, V67, P305 CAPLUS
- (48) Traversa, G; Epidemiology 1995, V6, P49 MEDLINE
- (49) Vane, J; Inflamm Res 1995, V44, P1 CAPLUS
- (50) Wallace, J; Can J Physiol Pharmacol 1994, V72, P1493 CAPLUS
- (51) Whittle, B; Aspirin and other salicylates 1992, P465 CAPLUS
- (52) Wiesenberger-Bottcher, I; Agents Actions 1989, V26, P240 MEDLINE
- (53) Wong, E; Inflamm Res 1997, V46, P51 CAPLUS

=> d 116 54 all

L16 ANSWER 54 OF 54 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:69065 CAPLUS
 DN 120:69065
 TI Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of
 constitutive and inducible cyclooxygenase
 AU Mitchell, Jane A.; Akarasereenont, Pravitt; Thiemermann, Christoph; Flower,
 Roderick J.; Vane, John R.
 CS Med. Coll., St. Bartholomew's Hosp., London, EC1M 6BQ, UK
 SO Proceedings of the National Academy of Sciences of the United States of
 America (1993), 90(24), 11693-7

CODEN: PNASA6; ISSN: 0027-8424

DT Journal

LA English

CC 1-7 (Pharmacology)

AB Constitutive arachidonate cyclooxygenase (COX-1) is present in cells under
physiol. conditions, whereas inducible arachidonate cyclooxygenase (
COX-2) is induced by some cytokines, mitogens, and
endotoxin presumably in pathol. conditions, such as inflammation.
Therefore, the authors have assessed the relative inhibitory effects of
some nonsteroidal antiinflammatory drugs on the activities of COX-1 (in
bovine aortic endothelial cells) and **COX-2** (in
endotoxin-activated J774.2 macrophages) in intact cells, broken cells, and
purified enzyme preps. (COX-1 in sheep seminal vesicles; **COX-2**
in sheep placenta). Similar potencies of aspirin, indomethacin,
and ibuprofen against the broken cell and purified enzyme preps.
indicated no influence of species. Aspirin, indomethacin, and ibuprofen
were more potent inhibitors of COX-1 than **COX-2** in all
models used. The relative potencies of aspirin and indomethacin varied
only slightly between models, although the IC50 values were different.
Ibuprofen was more potent as an inhibitor of **COX-2** in
intact cells than in either broken cells or purified enzymes. Sodium
salicylate was a weak inhibitor of both COX isoforms in intact cells and
was inactive against COX in either broken cells or purified enzyme preps.
Diclofenac, BW755C, acetaminophen, and naproxen were approx. equipotent
inhibitors of COX-1 and **COX-2** in intact cells. BF
389, an exptl. drug currently being tested in humans, was the most potent
and most selective inhibitor of **COX-2** in intact cells.
Thus, there are clear pharmacol. differences between the two enzymes. The
use of such models of COX-1 and **COX-2** activity will
lead to the identification of selective inhibitors of **COX-2**
with presumably less side effects than present therapies. Some
inhibitors had higher activity in intact cells than against purified
enzymes, suggesting that pure enzyme preps. may not be predictive of
therapeutic action.

ST arachidonate cyclooxygenase inhibitor nonsteroidal antiinflammatory drug
IT Inflammation inhibitors

(nonsteroidal, constitutive and inducible arachidonate cyclooxygenase
inhibition by,)

IT 39391-18-9, Arachidonate cyclooxygenase

RL: BIOL (Biological study)

(1 and 2, inhibition of, by nonsteroidal antiinflammatory drugs,
selectivity of)

IT 69-72-7, Salicylic acid, biological studies 15307-86-5, Diclofenac

22204-53-1, Naproxen 66000-40-6, BW755C 127245-22-1, BF 389

RL: BIOL (Biological study)

(constitutive and inducible arachidonate cyclooxygenase inhibition by,)

IT 50-78-2, Aspirin 53-86-1, Indomethacin **103-90-2**, Acetaminophen

15687-27-1, Ibuprofen

RL: BIOL (Biological study)

(constitutive and inducible arachidonate cyclooxygenase inhibition by,
selectivity of)

=> d his

(FILE 'HOME' ENTERED AT 14:08:00 ON 07 AUG 2003)

FILE 'REGISTRY' ENTERED AT 14:08:06 ON 07 AUG 2003

L1 0 S ACETAMINOOPHEN

L2 130 S ACETAMINOPHEN

FILE 'CA' ENTERED AT 14:08:53 ON 07 AUG 2003

E HOMOCYSTENE
E HOMOCYSTEINE
L3 7530 S E3
L4 0 S L1
L5 10702 S L2
L6 9 S L5 AND L3

FILE 'CAPLUS' ENTERED AT 14:11:10 ON 07 AUG 2003

L7 9 S L2 AND L3
E PLAQUE
L8 21528 S E3
L9 43 S L8 AND L3
L10 6 S L5 AND L8
E VASCULAR
L11 114286 S E3
L12 52 S L11 AND L5
L13 5160 S COX-2
E ATHEROSCLEROSIS
L14 35977 S E3
L15 104 S L13 AND L14
L16 54 S L5 AND L13

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	230.94	251.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-9.77	-9.77

STN INTERNATIONAL LOGOFF AT 14:58:42 ON 07 AUG 2003

LA Russian

L16 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1971:21314 CAPLUS

DN 74:21314

TI Disturbance of brain metabolism during experimental **atherosclerosis** and fatigue

AU Turova, N. F.; Pogodaev, K. I.

CS Mosk. Med. Inst. im. Sechenova, Moscow, USSR

SO Tr. Vses. Konf. Biokhim. Nerv. Sist., 4th (1969), Meeting Date 1966, 176-85. Editor(s): Tahepold, L. Publisher: Tartu. Gos. Univ., Tartu, USSR.

CODEN: 22KAAS

DT Conference

LA Russian

L16 ANSWER 314 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1970:433282 CAPLUS

DN 73:33282

TI Role of hormonal shifts in the disturbance of lipometabolism and the development of atherosclerotic changes

AU Panin, L. E.

CS Tsent. Nauch.-Issled. Lab., Tomsk. Med. Inst., Tomsk, USSR

SO Tr. Kuibyshev. Med. Inst. (1969), 56, 128-32

CODEN: TKUMA9

DT Journal

LA Russian

L16 ANSWER 315 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1969:489445 CAPLUS

DN 71:89445

TI Effect of glycogen with adrenaline on experimental **atherosclerosis**

AU Nityanand, Swarn; Kapoor, Narinder K.

CS Cent. Drug. Res. Inst., Lucknow, India

SO Indian J. Exp. Biol. (1969), 7(3), 140-2

CODEN: IJEBA6

DT Journal

LA English

L16 ANSWER 316 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1969:488144 CAPLUS

DN 71:88144

TI Effects of adrenaline on the bioelectrical activity of the brain

AU Voloshin, P. V.; Dubenko, E. G.; Binevskaya, O. M.; Podguzova, K. L.; Sheiko, N. I.

CS Med. Inst., Kharkov, USSR

SO Gormony Golovnoi Mozg, Tr. Vses. Nauch. Konf. (1968), Meeting Date 1967, 148-52. Editor(s): Komissarenko, V. P. Publisher: Nauk. Dumka, Kiev, USSR.

CODEN: 21HRAN

DT Conference

LA Russian

L16 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2002 ACS

AN 1969:93663 CAPLUS

DN 70:93663

TI **Atherosclerosis** in rabbits caused by prolonged injection of adrenaline

AU Popov, A. V.

CS Leningrad. Pediat. Med. Inst., Leningrad, USSR

SO Patol. Fiziol. Eksp. Ter. (1969), 13(1), 83-4

CODEN: PAFEAY

cyclooxygenase-2 (COX-2) inhibitor for reducing the risks associated with
cardio- and cerebrovascular disease

IN Winokur, Melvin
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9920110	A1	19990429	WO 1998-US21901	19981016
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2306646	AA	19990429	CA 1998-2306646	19981016
	AU 9913612	A1	19990510	AU 1999-13612	19981016
	AU 753657	B2	20021024		
	EP 1024696	A1	20000809	EP 1998-957328	19981016
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	JP 2001520174	T2	20011030	JP 2000-516533	19981016
	US 6245797	B1	20010612	US 1998-179349	19981020
PRAI	US 1997-62691P	P	19971022		
	GB 1998-6688	A	19980327		
	WO 1998-US21901	W	19981016		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 108 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:193844 CAPLUS
DN 130:227739
TI Method for lowering serum lipid levels employing an MTP inhibitor in
combination with another cholesterol lowering drug
IN Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II
PA Bristol-Myers Squibb Company, USA
SO U.S., 22 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5883109	A	19990316	US 1997-854311	19970512

OS MARPAT 130:227739

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 109 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:184130 CAPLUS
DN 130:205139
TI Combination therapy comprising atorvastatin and an antihypertensive agent
IN Scott, Robert Andrew Donald
PA Pfizer Inc., USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911260	A1	19990311	WO 1998-IB1230	19980811
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9884589	A1	19990322	AU 1998-84589	19980811
	AU 740424	B2	20011101		
	EP 1009400	A1	20000621	EP 1998-935250	19980811
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9811556	A	20000822	BR 1998-11556	19980811
	JP 2001514223	T2	20010911	JP 2000-508363	19980811
	ZA 9807839	A	20000228	ZA 1998-7839	19980828
	NO 2000000996	A	20000427	NO 2000-996	20000228
	US 2002099046	A1	20020725	US 2001-45329	20011023
PRAI	US 1997-57276P	P	19970829		
	WO 1998-IB1230	W	19980811		
	US 2000-513887	B1	20000225		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 110 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1999:184129 CAPLUS

DN 130:205138

TI Therapeutic combinations comprising amlodipine and atorvastatin

IN Buch, Jan; Scott, Robert Andrew Donald

PA Pfizer Inc., USA

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911259	A1	19990311	WO 1998-IB1225	19980811
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2301732	AA	19990311	CA 1998-2301732	19980811
	AU 9885548	A1	19990322	AU 1998-85548	19980811
	EP 1003503	A1	20000531	EP 1998-936587	19980811
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9812030	A	20000926	BR 1998-12030	19980811
	JP 2001514222	T2	20010911	JP 2000-508362	19980811
	ZA 9807844	A	20000228	ZA 1998-7844	19980828
	US 6455574	B1	20020924	US 2000-512914	20000225
	NO 2000000998	A	20000228	NO 2000-998	20000228
PRAI	US 1997-57275P	P	19970829		
	WO 1998-IB1225	W	19980811		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 111 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:159872 CAPLUS
DN 130:246722
TI Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols
AU Cziraky, Mark
CS Health Core, Newark, DE, USA
SO PharmacoEconomics (1998), 14(Suppl. 3), 29-38
CODEN: PARMEK; ISSN: 1170-7690
PB Adis International Ltd.
DT Journal
LA English

RE.CNT 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 112 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:113552 CAPLUS
DN 130:173009
TI Combinations of HMG-CoA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia
IN Bova, David J.; Dunne, Josephine
PA Kos Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906046	A1	19990211	WO 1998-US15989	19980731
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2001006644	A1	20010705	US 1997-903871	19970731
	AU 9886800	A1	19990222	AU 1998-86800	19980731
	EP 1003515	A1	20000531	EP 1998-938227	19980731
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	NO 2000000407	A	20000316	NO 2000-407	20000127
PRAI	US 1997-903871	A	19970731		
	WO 1998-US15989	W	19980731		

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 113 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1999:113543 CAPLUS
DN 130:187186
TI Pharmaceutical composition containing combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds for treating hyperlipidemia once a day at night
IN Bova, David J.; Dunne, Josephine
PA Kos Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906035	A2	19990211	WO 1998-US15990	19980731
	WO 9906035	A3	19990422		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9886801	A1	19990222	AU 1998-86801	19980731
	AU 752673	B2	20020926		
	EP 1017390	A2	20000712	EP 1998-938228	19980731
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	BR 9815548	A	20001107	BR 1998-15548	19980731
	JP 2001511444	T2	20010814	JP 2000-504849	19980731
	NO 2000000439	A	20000322	NO 2000-439	20000127
PRAI	US 1997-903752	A	19970731		
	WO 1998-US15990	W	19980731		

L22 ANSWER 114 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1999:1203 CAPLUS

DN 130:218023

TI HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of **atherosclerosis**

AU Bustos, Carmen; Hernandez-Presa, Miguel A.; Ortego, Monica; Tunon, Jose; Ortega, Luis; Perez, Fernando; Diaz, Cristina; Hernandez, Gonzalo; Egido, Jesus

CS Fundacion Jimenez Diaz, Universidad Autonoma, Madrid, 28040, Spain

SO Journal of the American College of Cardiology (1998), 32(7), 2057-2064
CODEN: JACCDI; ISSN: 0735-1097

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 115 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1998:744939 CAPLUS

DN 130:17236

TI MTP inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

IN Gregg, Richard E.; Wetterau, John R., II

PA Bristol-Myers Squibb Co., USA

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850028	A1	19981112	WO 1998-US8269	19980423
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,			

UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9871559 A1 19981127 AU 1998-71559 19980423
 AU 748608 B2 20020606
 EP 1024804 A1 20000809 EP 1998-918680 19980423
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI

JP 2001527551 T2 20011225 JP 1998-548138 19980423

PRAI US 1997-45405P P 19970501
 WO 1998-US8269 W 19980423

OS MARPAT 130:17236

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 116 OF 130 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:625982 CAPLUS
 DN 130:20459
 TI Treating patients with documented **atherosclerosis** to national
 cholesterol education program-recommended low-density-lipoprotein
 cholesterol goals with atorvastatin, fluvastatin, lovastatin and
 simvastatin

AU Brown, Alan S.; Bakker-Arkema, Rebecca G.; Yellen, Laurence; Henley,
 Robert W., Jr.; Guthrie, Richard; Campbell, Cam F.; Koren, Michael; Woo,
 William; McLain, Richard; Black, Donald M.

CS Midwest Heart Research Foundation, Naperville, IL, USA
 SO Journal of the American College of Cardiology (1998), 32(3), 665-672
 CODEN: JACCDI; ISSN: 0735-1097

PB Elsevier Science Inc.
 DT Journal
 LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 117 OF 130 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:509102 CAPLUS
 DN 129:153237
 TI Method for treating **atherosclerosis** with an MPT inhibitor and
 cholesterol-lowering drugs

IN Behounek, Bruce D.; MCGovern, Mark E.; Belder, Rene
 PA Bristol-Myers Squibb Co., USA
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9831366	A1	19980723	WO 1998-US524	19980112
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9862397	A1	19980807	AU 1998-62397	19980112
AU 727895	B2	20010104		
EP 989852	A1	20000405	EP 1998-904548	19980112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI
JP 2001508795 T2 20010703 JP 1998-534460 19980112
PRAI US 1997-35592P P 19970117
WO 1998-US524 W 19980112
OS MARPAT 129:153237
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 118 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1998:478194 CAPLUS
DN 129:225548
TI LPS-induced cytokine production and expression of LPS-receptors by
peripheral blood mononuclear cells of patients with familial
hypercholesterolemia and the effect of HMG-CoA reductase inhibitors
AU de Bont, Natasja; Netea, Mihai G.; Rovers, Chantal; Smilde, Tineke;
Demacker, Pierre N. M.; van der Meer, Jos W. M.; Stalenhoef, Anton F. H.
CS Department of Medicine, Division of General Internal Medicine, University
Hospital Nijmegen, Nijmegen, 6500 HB, Neth.
SO Atherosclerosis (Shannon, Ireland) (1998), 139(1), 147-152
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 119 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1998:478160 CAPLUS
DN 129:225547
TI HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma
cholesterol and limit atherosclerotic lesion development in the
cholesterol-fed rabbit
AU Bocan, Thomas M. A.; Bak Mueller, Sandra; Quenby Brown, Edie; Lee, Peter;
Bocan, Michelle J.; Rea, Thomas; Pape, Michael E.
CS Parke-Davis Pharmaceutical Research, Department of Vascular and Cardiac
Diseases, Division of Warner Lambert Company, Ann Arbor, MI, 48105, USA
SO Atherosclerosis (Shannon, Ireland) (1998), 139(1), 21-30
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 120 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1998:458053 CAPLUS
DN 129:184104
TI Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are
potent antioxidants against lipoprotein oxidation
AU Aviram, Michael; Rosenblat, Mira; Bisgaier, Charles L.; Newton, Roger S.
CS Technion Faculty of Medicine, Rappaport Family Institute for Research in
the Medical Sciences and Rambam Medical Center, Haifa, 31096, Israel
SO Atherosclerosis (Shannon, Ireland) (1998), 138(2), 271-280
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English

L22 ANSWER 121 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1998:404579 CAPLUS
DN 129:130773
TI Advances in drug treatment of dyslipidemia: focus on atorvastatin

AU Davignon, Jean
 CS Hyperlipidemia and Atherosclerosis Research Group, Clinical Research
 Institute of Montreal, Montreal, QC, H2W 1R7, Can.
 SO Canadian Journal of Cardiology (1998), 14(Suppl. B), 28B-38B
 CODEN: CJCAEX; ISSN: 0828-282X
 PB Pulsus Group
 DT Journal; General Review
 LA English

L22 ANSWER 122 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1998:400182 CAPLUS

DN 129:131131

TI Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors,
 atorvastatin and simvastatin, on the expression of endothelin-1 and
 endothelial nitric oxide synthase in vascular endothelial cells

AU Hernandez-Perera, Octavio; Perez-Sala, Dolores; Navarro-Antolin, Javier;
 Sanchez-Pascuala, Rafael; Hernandez, Gonzalo; Diaz, Cristina; Lamas,
 Santiago

CS Centro de Investigaciones Biologicas, Instituto Reina Sofia de
 Investigaciones Nefrologicas, Consejo Superior de Investigaciones
 Cientificas, Madrid, 28006, Spain

SO Journal of Clinical Investigation (1998), 101(12), 2711-2719
 CODEN: JCINAO; ISSN: 0021-9738

PB Rockefeller University Press

DT Journal

LA English

L22 ANSWER 123 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1998:388501 CAPLUS

DN 129:54297

TI Apo B-secretion/MTP inhibitory 4'-(trifluoromethyl)biphenyl-2-carboxylic
 acid (1,2,3,4-tetrahydroisoquinolin-6-yl)amides and their preparation,
 pharmaceutical compositions, and use

IN Chang, George; Quallich, George Joseph

PA Pfizer Inc., USA; Chang, George; Quallich, George Joseph

SO PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9823593	A1	19980604	WO 1997-IB1368	19971103
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9746347	A1	19980622	AU 1997-46347	19971103
	AU 716151	B2	20000217		
	EP 944602	A1	19990929	EP 1997-945048	19971103
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	CN 1238764	A	19991215	CN 1997-180033	19971103
	BR 9714364	A	20000321	BR 1997-14364	19971103
	JP 2000505810	T2	20000516	JP 1998-524464	19971103
	JP 3270764	B2	20020402		
	ZA 9710641	A	19990526	ZA 1997-10641	19971126
	US 6121283	A	20000919	US 1999-284466	19990420

NO 9902525 A 19990526 NO 1999-2525 19990526
 KR 2000057269 A 20000915 KR 1999-704662 19990526
 PRAI US 1996-32307P P 19961127
 WO 1997-IB1368 W 19971103
 OS CASREACT 129:54297; MARPAT 129:54297
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 124 OF 130 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:87580 CAPLUS
 DN 128:162883
 TI Method for lowering serum lipid levels employing a microsomal
 triglyceride-transfer protein (MTP) inhibitor in combination with another
 cholesterol-lowering drug
 IN Gregg, Richard E.; Pouleur, Hubert G.; Wetterau, John R., II
 PA Bristol-Myers Squibb Co., USA
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803069	A1	19980129	WO 1997-US12229	19970714
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9705950	A	19990104	ZA 1997-5950	19970703
	AU 9736624	A1	19980210	AU 1997-36624	19970714
	AU 716145	B2	20000217		
	EP 1014791	A1	20000705	EP 1997-933435	19970714
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000515526	T2	20001121	JP 1998-507023	19970714
PRAI	US 1996-22866P	P	19960724		
	WO 1997-US12229	W	19970714		
OS	MARPAT 128:162883				

L22 ANSWER 125 OF 130 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:778860 CAPLUS
 DN 128:70496
 TI Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle
 cells
 AU Baetta, Roberta; Donetti, Elena; Comparato, Carmen; Calore, Monica; Rossi,
 Alessandra; Teruzzi, Chiara; Paoletti, Rodolfo; Fumagalli, Remo; Soma,
 Maurizio R.
 CS Institute of Pharmacological Sciences, University of Milan, Milan, 20133,
 Italy
 SO Pharmacological Research (1997), 36(2), 115-121
 CODEN: PHMREP; ISSN: 1043-6618
 PB Academic Press Ltd.
 DT Journal
 LA English

L22 ANSWER 126 OF 130 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:696637 CAPLUS
 DN 127:351217

TI Combination therapy containing HMG-CoA reductase inhibitors for reducing
the risks associated with cardiovascular disease
IN Tobert, Jonathan A.
PA Merck & Co., Inc., USA; Tobert, Jonathan A.
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9738694	A1	19971023	WO 1997-US6127	19970414
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2251972	AA	19971023	CA 1997-2251972	19970414
	AU 9726665	A1	19971107	AU 1997-26665	19970414
	AU 732465	B2	20010426		
	EP 904082	A1	19990331	EP 1997-918595	19970414
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000508659	T2	20000711	JP 1997-537264	19970414
PRAI	US 1996-15689P	P	19960417		
	GB 1996-12082	A	19960610		
	US 1996-20977P	P	19960624		
	GB 1996-16804	A	19960809		
	WO 1997-US6127	W	19970414		

L22 ANSWER 127 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1997:576602 CAPLUS
DN 127:243263
TI Combination of a cholesterol biosynthesis inhibitor and a .beta.-lactam
cholesterol absorption inhibitor as antihypercholesterolemic
IN Davis, Harry R.
PA Schering Corporation, USA
SO U.S., 7 pp., Cont.-in-part of U.S. Ser. No. 995,488, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5661145	A	19970826	US 1995-454348	19950620
	WO 9414433	A1	19940707	WO 1993-US12291	19931221
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI	US 1992-995488	B2	19921223		
	WO 1993-US12291	W	19931221		
OS	MARPAT 127:243263				

L22 ANSWER 128 OF 130 CAPLUS COPYRIGHT 2002 ACS
AN 1997:356461 CAPLUS
DN 126:330797
TI Preparation of steroidal glycosides for treatment of hypercholesterolemia
and related disorders
IN Kim, Dooseop
PA Merck and Co., Inc., USA

SO Brit. UK Pat. Appl., 78 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2304106	A1	19970312	GB 1996-16443	19960805
PRAI	US 1995-2039P	P	19950808		
OS	MARPAT 126:330797				

L22 ANSWER 129 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1997:280110 CAPLUS

DN 126:325296

TI Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

AU Bertolini, Stefano; Bittolo Bon, Gabriele; Campbell, L. Malcolm; Farnier, Michel; Langan, John; Mahla, Gerhard; Pauciullo, Paolo; Sirtori, Cesare; Egros, Fabrice; Fayyad, Rana; Nawrocki, James W.

CS Dipartimento di Medicina Interna, Genoa, Italy

SO Atherosclerosis (Shannon, Ireland) (1997), 130(1,2), 191-197

CODEN: ATHSBL; ISSN: 0021-9150

PB Elsevier

DT Journal

LA English

L22 ANSWER 130 OF 130 CAPLUS COPYRIGHT 2002 ACS

AN 1996:431460 CAPLUS

DN 125:76399

TI Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor for treatment of hypercholesterolemia and **atherosclerosis**

IN Morehouse, Lee A.

PA Morehouse, Lee, A., USA

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9609827	A2	19960404	WO 1995-IB447	19950607
	WO 9609827	A3	19960523		
	W: AU, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, SI, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2200436	AA	19960404	CA 1995-2200436	19950607
	AU 9524532	A1	19960419	AU 1995-24532	19950607
	EP 782451	A1	19970709	EP 1995-918721	19950607
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09511753	T2	19971125	JP 1995-511549	19950607
	BR 9504072	A	19960730	BR 1995-4072	19950919
	ZA 9507879	A	19970319	ZA 1995-7879	19950919
	US 5807834	A	19980915	US 1997-793802	19970318
	FI 9701151	A	19970319	FI 1997-1151	19970319
PRAI	US 1994-308908	A	19940920		
	WO 1995-IB447	W	19950607		
OS	MARPAT 125:76399				

=> s 18

L23 8582 L8

=> s 123 and 110
L24 31 L23 AND L10

=> d 124 1-31

L24 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 2002:814844 CAPLUS
DN 137:304788
TI Novel structures comprising phytosterol and/or phytostanol and ascorbic acid and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
IN Kutney, James P.; Milanova, Radka K.; Ding, Yangbing; Chen, Hongming; Hou, Duanjie
PA Forbes Medi-Tech Inc., USA
SO U.S. Pat. Appl. Publ., 35 pp., Cont.-in-part of U.S. Ser. No. 339,903, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002156051	A1	20021024	US 2001-916817	20010725
PRAI	US 1999-339903	B2	19990623		
OS	MARPAT 137:304788				

L24 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 2002:717065 CAPLUS
DN 137:226613
TI Use of acetaminophen to prevent and treat arteriosclerosis
IN Nelson, Edward B.; Smith, Charles V.; Taylor, Addison A.
PA USA
SO U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002132855	A1	20020919	US 2001-887465	20010622
PRAI	US 2000-222781P	P	20000803		

L24 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 2002:574926 CAPLUS
DN 137:135094
TI The use of substituted azetidinone compounds for the treatment of sitosterolemia
IN Davis, Harry R.
PA Schering Corporation, USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002058696	A2	20020801	WO 2002-US1195	20020125
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002169134 A1 20021114 US 2002-57629 20020125
PRAI US 2001-264645P P 20010126
OS MARPAT 137:135094

L24 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2002:550280 CAPLUS

DN 137:273340

TI Prospective study of effect of androgens on serum inflammatory markers in men

AU Ng, Martin K. C.; Liu, Peter Y.; Williams, Andrew J.; Nakhla, Shirley; Ly, Lam P.; Handelsman, David J.; Celemajer, David S.

CS Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia
SO Arteriosclerosis, Thrombosis, and Vascular Biology (2002), 22(7), 1136-1141

CODEN: ATVBFA; ISSN: 1079-5642

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2002:209862 CAPLUS

DN 136:335386

TI Effects of dehydroepiandrosterone on rat apolipoprotein AI gene expression in the human hepatoma cell line, HepG2

AU Deleon, Mary Jeanne; Horani, Mohamad H.; Haas, Michael J.; Wong, Norman C. W.; Mooradian, Arshag D.

CS Division of Endocrinology, Diabetes, Saint Louis University School of Medicine, St Louis, MO, 63104, USA

SO Metabolism, Clinical and Experimental (2002), 51(3), 376-379

CODEN: METAAJ; ISSN: 0026-0495

PB W. B. Saunders Co.

DT Journal

LA English

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2002:51305 CAPLUS

DN 136:123597

TI Preparation of stable radiopharmaceutical compositions useful for tumor therapy

IN Liu, Shuang; Barrett, John A.; Carpenter, Alan P., Jr.

PA Dupont Pharmaceuticals Company, USA

SO PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004030	A2	20020117	WO 2001-US21261	20010705

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,

ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2002122768 A1 20020905 US 2001-899629 20010705
 PRAI US 2000-216396P P 20000706
 OS MARPAT 136:123597

L24 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:935597 CAPLUS
 DN 136:54028
 TI Preparation of vitronectin receptor antagonist pharmaceuticals
 IN Rajopadhye, Milind; Barrett, John A.; Carpenter, Alan P., Jr.; Cheesman,
 Edward H.; Harris, Thomas D.
 PA Dupont Pharmaceuticals Company, USA
 SO PCT Int. Appl., 449 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001098294	A2	20011227	WO 2001-US19794	20010621
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				
	HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				
	LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				
	SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,				
	ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-213212P	P	20000621		
OS	MARPAT 136:54028				

L24 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:676782 CAPLUS
 DN 135:231714
 TI Phytosterols and/or phytostanols and .alpha.-lipoic acid for treatment of
 cardiovascular diseases
 IN Milanova, Radka K.; Kutney, James P.; Novak, Egon; Hou, Duanjie
 PA Forbes Medi-Tech Inc., Can.
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066560	A2	20010913	WO 2001-CA285	20010307
	WO 2001066560	A3	20020328		
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
	DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,				
	JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,				
	MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,				
	TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,				
	RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU	2001042130	A5	20010917	AU 2001-42130	20010307
PRAI	US 2000-519278	A	20000307		

WO 2001-CA285 W 20010307
OS MARPAT 135:231714

L24 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 2001:545714 CAPLUS
DN 135:127171
TI Novel crystalline composites comprising phytosterols and phytostanols or derivatives thereof
IN Stewart, David John
PA Forbes Medi-Tech Inc., Can.
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053320	A2	20010726	WO 2001-CA53	20010122
	WO 2001053320	A3	20010927		
	WO 2001053320	C2	20020718		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001028221	A5	20010731	AU 2001-28221	20010122
	EP 1250350	A2	20021023	EP 2001-942633	20010122
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-489541	A	20000121		
	WO 2001-CA53	W	20010122		

L24 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 2001:537045 CAPLUS
DN 135:330892
TI Dietary vegetable oil and wood derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE*3-Leiden transgenic mice
AU Volger, O. L.; Mensink, R. P.; Plat, J.; Hornstra, G.; Havekes, L. M.; Princen, H. M. G.
CS Gaubius Lab. TNO-PG, Leiden, 2301 CE, Neth.
SO Atherosclerosis (Shannon, Ireland) (2001), 157(2), 375-381
CODEN: ATHSBL; ISSN: 0021-9150
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 2001:431184 CAPLUS
DN 135:236225
TI Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment
AU Moghadasian, Mohammed H.; Nguyen, Lien B.; Shefer, Sarah; Salen, Gerald; Batta, Ashok K.; Frohlich, Jiri J.
CS Department of Pathology and Laboratory Medicine, St. Paul's Hospital and University of British Columbia, Vancouver, BC, V6Z 1Y6, Can.

SO Metabolism, Clinical and Experimental (2001), 50(6), 708-714
CODEN: METAAJ; ISSN: 0026-0495
PB W. B. Saunders Co.
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 2001:338548 CAPLUS
DN 134:326708
TI Preparation of glycosides comprising pentose mono-, di-, tri-, or
oligosaccharides and phytosterols and/or phytostanols
IN Kutney, James P.; Milanova, Radka K.; Chen, Honming; Stoynov, Nikolay
Mintchev
PA Forbes Medi-Tech Inc., Can.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032679	A2	20010510	WO 2000-CA1272	20001101
	WO 2001032679	A3	20011025		
	WO 2001032679	C2	20020829		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001011223	A5	20010514	AU 2001-11223	20001101
PRAI	US 1999-432836	A	19991101		
	WO 2000-CA1272	W	20001101		
OS	CASREACT 134:326708; MARPAT 134:326708				

L24 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 2001:338288 CAPLUS
DN 134:339855
TI Compositions comprising edible oils or fats and phytosterols and/or
phytostanols substantially dissolved therein, method of making the same,
and use thereof in treating or preventing cardiovascular disease and its
underlying conditions
IN Zawistowski, Jerzy
PA Forbes Medi-Tech Inc., Can.
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032029	A2	20010510	WO 2000-CA1298	20001103
	WO 2001032029	A3	20010920		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,			

UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 2001012608 A5 20010514 AU 2001-12608 20001103
 EP 1227734 A2 20020807 EP 2000-974202 20001103
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRAI US 1999-434356 A 19991103
 US 1999-434256 A 19991103
 WO 2000-CA1298 W 20001103

L24 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2001:12478 CAPLUS

DN 134:71758

TI Synthesis of conjugates of phytosterol or phytostanol with ascorbic acid
 and use thereof in treating or preventing cardiovascular disease

IN Kutney, James P.; Ding, Yangbing; Chen, Honming; Hou, Duanjie; Milanova,
 Radka K.

PA Forbes Medi-Tech Inc., Can.

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001000653	A1	20010104	WO 2000-CA730	20000620
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1189924	A1	20020327	EP 2000-938426	20000620
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NO 2001006294	A	20020222	NO 2001-6294	20011220
PRAI	US 1999-339903	A	19990623		
	WO 2000-CA730	W	20000620		

OS MARPAT 134:71758

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:755213 CAPLUS

DN 133:325634

TI Soy protein and plant sterol containing composition for the reduction of
 low density lipoprotein cholesterol concentration

IN Waggle, Doyle H.

PA Protein Technologies International, Inc., USA

SO Eur. Pat. Appl., 19 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1046396	A2	20001025	EP 2000-303275	20000418

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

AU 748782	B2	20020613	AU 2000-27714	20000412
CA 2306008	AA	20001023	CA 2000-2306008	20000418
BR 2000001672	A	20010821	BR 2000-1672	20000420
JP 2000344676	A2	20001212	JP 2000-122241	20000424
CN 1323544	A	20011128	CN 2000-120362	20000513
US 2001029248	A1	20011011	US 2001-821860	20010330
AU 2002033001	A5	20020606	AU 2002-33001	20020409
AU 2002033002	A5	20020606	AU 2002-33002	20020409
AU 2002033003	A5	20020606	AU 2002-33003	20020409
PRAI US 1999-298528	A	19990423		
AU 2000-27714	A3	20000412		

L24 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:456922 CAPLUS

DN 133:94515

TI Combinations for cardiovascular indications

IN Keller, Bradley T.; Reitz, David B.; Schuh, Joseph R.; Sikorski, James A.;
Tremont, Samuel J.; Lappe, Rodney W.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 248 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038725	A1	20000706	WO 1999-US27946	19991217
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1140187	A1	20011010	EP 1999-965901	19991217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
	BR 9916564	A	20020129	BR 1999-16564	19991217
	JP 2002533411	T2	20021008	JP 2000-590676	19991217
	NO 2001003157	A	20010822	NO 2001-3157	20010622
PRAI	US 1998-113955P	P	19981223		
	WO 1999-US27946	W	19991217		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 2000:325040 CAPLUS

DN 133:84439

TI Physiological responses associated with sustained delivery of T, DHT, and AED in male rats

AU Stokes, Keith I.; Benguzzi, Hamed A.; Cameron, Joseph A.

CS Jackson State University, Jackson, MS, 39204, USA

SO Biomedical Sciences Instrumentation (2000), 36, 209-214

CODEN: BMSIA7; ISSN: 0067-8856

PB Instrument Society of America

DT Journal

LA English

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:90255 CAPLUS
 DN 132:246478
 TI Androgen receptor expression is greater in macrophages from male than from female donors: a sex difference with implications for atherogenesis
 AU McCrohon, Jane A.; Death, Alison K.; Nakhla, Shirley; Jessup, Wendy; Handelsman, David J.; Stanley, Keith K.; Celermajer, David S.
 CS Heart Research Institute, Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia
 SO Circulation (2000), 101(3), 224-226
 CODEN: CIRCAZ; ISSN: 0009-7322
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:316828 CAPLUS
 DN 131:125622
 TI Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1
 AU McCrohon, Jane A.; Jessup, Wendy; Handelsman, David J.; Celermajer, David S.
 CS Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia
 SO Circulation (1999), 99(17), 2317-2322
 CODEN: CIRCAZ; ISSN: 0009-7322
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:161434 CAPLUS
 DN 130:347115
 TI Lack of regression of atherosclerotic lesions in phytosterol-treated APO E-deficient mice
 AU Moghadasian, Mohammed H.; Godin, David V.; McManus, Bruce M.; Frohlich, Jiri J.
 CS Healthy Heart Program and Department of Pathology and Laboratory Medicine, St. Paul's Hospital, University of British Columbia, Vancouver, BC, V6Z 1Y6, Can.
 SO Life Sciences (1999), 64(12), 1029-1036
 CODEN: LIFSAK; ISSN: 0024-3205
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:284633 CAPLUS
 DN 129:62731
 TI Dietary sitostanol reduces plaque formation but not lecithin cholesterol acyl transferase activity in rabbits
 AU Ntanios, Fady Y.; Jones, Peter J. H.; Frohlich, Jiri J.
 CS School of Dietetics and Human Nutrition, McGill University, Ste-Anne-de-Bellevue, QC, H9X 3V9, Can.

SO Atherosclerosis (Shannon, Ireland) (1998), 138(1), 101-110
 CODEN: ATHSBL; ISSN: 0021-9150
 PB Elsevier Science Ireland Ltd.
 DT Journal
 LA English

L24 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:355494 CAPLUS
 DN 127:106258
 TI Rapid hydrogenation of unsaturated sterols and bile alcohols using microwaves
 AU Dayal, B.; Ertel, N. H.; Rapole, K. R.; Asgaonkar, A.; Salen, G.
 CS Medical Service, Department of Veterans Affairs Medical Center, Eash Orange, NJ, USA
 SO Steroids (1997), 62(5), 451-454
 CODEN: STEDAM; ISSN: 0039-128X
 PB Elsevier
 DT Journal
 LA English

L24 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1996:702147 CAPLUS
 DN 126:5770
 TI Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease
 AU Gylling, Helena; Miettinen, Tatu A.
 CS Dep. Med., Univ. Helsinki, Helsinki, FIN-00290, Finland
 SO Atherosclerosis (Shannon, Ireland) (1996), 126(2), 325-332
 CODEN: ATHSBL; ISSN: 0021-9150
 PB Elsevier
 DT Journal
 LA English

L24 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1994:549373 CAPLUS
 DN 121:149373
 TI Androgen receptors, 5.alpha.-reductase activity and androgen-dependent proliferation of vascular smooth muscle cells
 AU Fujimoto, Ryoji; Morimoto, Isao; Morita, Emiko; Sugimoto, Hidekatsu; Ito, Yukio; Eto, Sumiya
 CS First Department of Internal Medicine, University of Occupational and Environmental Health, Yahatanishi, 807, Japan
 SO Journal of Steroid Biochemistry and Molecular Biology (1994), 50(3-4), 169-74
 CODEN: JSBBEZ; ISSN: 0960-0760
 DT Journal
 LA English

L24 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:628895 CAPLUS
 DN 113:228895
 TI A molecular defect in hepatic cholesterol biosynthesis in sitosterolemia with xanthomatosis
 AU Nguyen, Lien B.; Shefer, Sarah; Salen, Gerald; Ness, Gene C.; Tint, G. S.; Zaki, George; Rani, Indu
 CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103, USA
 SO Journal of Clinical Investigation (1990), 86(3), 923-31
 CODEN: JCINAO; ISSN: 0021-9738
 DT Journal
 LA English

L24 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2002 ACS

AN 1990:491594 CAPLUS
 DN 113:91594
 TI High-density lipoprotein response to 5- α -dihydrotestosterone and testosterone in *Macaca fascicularis*: a hormone-responsive primate model for the study of **atherosclerosis**
 AU Greger, Nancy G.; Insull, William, Jr.; Probstfield, Jeffrey L.; Keenan, Bruce S.
 CS Dep. Pediatr., Baylor Coll. Med., Houston, TX, USA
 SO Metabolism, Clinical and Experimental (1990), 39(9), 919-24
 CODEN: METAAJ; ISSN: 0026-0495
 DT Journal
 LA English

L24 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1977:463153 CAPLUS
 DN 87:63153
 TI Effect of dihydrotestosterone on the content of lipids in the blood serum and their distribution among the lipoprotein fractions in rabbits with experimental hyperlipidemia
 AU Sharkevich, I. N.; Fisun, S. D.
 CS Khar'k Nauchno-Issled. Inst. Endokrinol. Khim. Gorm., Kharkov, USSR
 SO Patol. Fiziol. Eksp. Ter. (1976), (2), 51-6
 CODEN: PAFEAY
 DT Journal
 LA Russian

L24 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:504236 CAPLUS
 DN 85:104236
 TI Mechanism of the hypolipidemic and antisclerotic effect of testosterone and its metabolites
 AU Genes, S. G.; Vasilenko, A. S.; Salimovskaya, I. N.; Sharkevich, I. N.; Yurchenko, M. Z.
 CS Khar'k. Nauchno-Issled. Inst. Endokrinol. Khim. Gorm., Kharkov, USSR
 SO S'ezd Vses. Fiziol. O-va. im. I. P. Pavlova, 12th (1975), Volume 2, 157-8.
 Editor(s): Bakuradze, A. N. Publisher: "Nauka", Leningr. Otd., Leningrad, USSR.
 CODEN: 33OCA4
 DT Conference
 LA Russian

L24 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1973:106135 CAPLUS
 DN 78:106135
 TI Effect of anabolic steroids and of strophanthin on the course of experimental **atherosclerosis** in rabbits accompanied by chronic hyperfunction of the left ventricle
 AU Bondarenko, I. P.
 CS Kharkov Med. Inst., Kharkov, USSR
 SO Byull. Eksp. Biol. Med. (1973), 75(1), 30-2
 CODEN: BEBMAE
 DT Journal
 LA Russian

L24 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2002 ACS
 AN 1972:456 CAPLUS
 DN 76:456
 TI Effects of dihydrotestosterone on serum lipids and the development of experimental **atherosclerosis** in rabbits
 AU Sharkevich, I. N.
 CS Khar'k. Nauchno-Issled. Inst. Endokrinol. Khim. Gorm., Kharkov, USSR
 SO Patol. Fiziol. Eksp. Ter. (1971), 15(4), 79-83

CODEN: PAFEAY
DT Journal
LA Russian

L24 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2002 ACS
AN 1963:35142 CAPLUS
DN 58:35142
OREF 58:6042b-d

TI Influence of corn oil on some indexes of lipid and protein metabolism in patients with **atherosclerosis**
AU Kozlovskii, V. N.
CS Main Military Hosp., Moscow
SO Klinich. Med. (1962), 40(No. 11), 112-15
DT Journal
LA Unavailable

=> s 19

L25 198 L9

=> s 125 and 110

L26 10 L25 AND L10

=> d 126 1-10

L26 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2002:540258 CAPLUS

DN 137:109267

TI Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors

IN Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing

PA USA

SO U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 875,155.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002094977	A1	20020718	US 2001-7407	20011204
	US 2002013334	A1	20020131	US 2001-875155	20010606
PRAI	US 2000-211595P	P	20000615		
	US 2001-875155	A2	20010606		
OS	MARPAT 137:109267				

L26 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2002:487404 CAPLUS

DN 137:47219

TI Preparation of pyrazolo[4,3-d]pyrimidine derivatives as phosphodiesterase V inhibitors and their pharmaceutical formulations containing antithrombotic, calcium antagonist, prostaglandin or prostaglandin derivative medicaments.

IN Eggenweiler, Hans-Michael; Eiermann, Volker

PA Merck Patent GmbH, Germany

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002049651	A1	20020627	WO 2001-EP13916	20011128
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				

CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
MA, MD, MG, MK, MN, MW, MX, NO, NZ, PH, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10063224 A1 20020620 DE 2000-10063224 20001219
DE 10063882 A1 20020711 DE 2000-10063882 20001221
DE 10064993 A1 20020704 DE 2000-10064993 20001223
AU 2002029573 A5 20020701 AU 2002-29573 20011128
PRAI DE 2000-10063224 A 20001219
DE 2000-10063882 A 20001221
DE 2000-10064993 A 20001223
WO 2001-EP13916 W 20011128

OS MARPAT 137:47219

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2002:487403 CAPLUS

DN 137:47218

TI Preparation of thieno[2,3-d]pyrimidine derivatives as phosphodiesterase V
inhibitors and their pharmaceutical formulations containing
antithrombotic, calcium antagonist, prostaglandin or prostaglandin
derivative medicaments.

IN Eggenweiler, Hans-Michael; Eiermann, Volker

PA Merck Patent Gmbh, Germany

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002049650	A2	20020627	WO 2001-EP13915	20011128
	WO 2002049650	A3	20021031		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PH, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10063223 A1 20020620 DE 2000-10063223 20001219
DE 10063885 A1 20020711 DE 2000-10063885 20001221
DE 10064992 A1 20020627 DE 2000-10064992 20001223
AU 2002027957 A5 20020701 AU 2002-27957 20011128

PRAI DE 2000-10063223 A 20001219
DE 2000-10063885 A 20001221
DE 2000-10064992 A 20001223
WO 2001-EP13915 W 20011128

OS CASREACT 137:47218; MARPAT 137:47218

L26 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2002:487402 CAPLUS

DN 137:47217

TI Preparation of benzothieno[2,3-d]pyrimidine derivatives as
phosphodiesterase V inhibitors and their pharmaceutical formulations

containing antithrombotic, calcium antagonist, prostaglandin or prostaglandin derivative medicaments.

IN Eggenweiler, Hans-Michael; Eiermann, Volker

PA Merck Patent GmbH, Germany

SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002049649	A2	20020627	WO 2001-EP13913	20011128
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10063221	A1	20020620	DE 2000-10063221	20001219
	DE 10063884	A1	20020627	DE 2000-10063884	20001221
	DE 10064991	A1	20020627	DE 2000-10064991	20001223
	AU 2002026362	A5	20020701	AU 2002-26362	20011128
PRAI	DE 2000-10063221	A	20001219		
	DE 2000-10063884	A	20001221		
	DE 2000-10064991	A	20001223		
	WO 2001-EP13913	W	20011128		
OS	CASREACT 137:47217; MARPAT 137:47217				

L26 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2002:462400 CAPLUS

DN 137:47210

TI Preparation of pyrazolo[4,3-d]pyrimidine derivatives as phosphodiesterase V inhibitors and their pharmaceutical formulations containing antithrombotic medicaments.

IN Eggenweiler, Hans-Michael; Eiermann, Volker

PA Merck Patent GmbH, Germany

SO Ger. Offen., 28 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10063224	A1	20020620	DE 2000-10063224	20001219
	WO 2002049651	A1	20020627	WO 2001-EP13916	20011128
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002029573	A5	20020701	AU 2002-29573	20011128
PRAI	DE 2000-10063224	A	20001219		
	DE 2000-10063882	A	20001221		
	DE 2000-10064993	A	20001223		
	WO 2001-EP13916	W	20011128		

OS CASREACT 137:47210; MARPAT 137:47210

L26 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2002:462399 CAPLUS

DN 137:47209

TI Preparation of thieno[2,3-d]pyrimidine derivatives as phosphodiesterase V inhibitors and their pharmaceutical formulations containing antithrombotic medicaments.

IN Eggenweiler, Hans-Michael; Eiermann, Volker

PA Merck Patent GmbH, Germany

SO Ger. Offen., 30 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10063223	A1	20020620	DE 2000-10063223	20001219
	WO 2002049650	A2	20020627	WO 2001-EP13915	20011128
	WO 2002049650	A3	20021031		
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002027957	A5	20020701	AU 2002-27957	20011128
PRAI	DE 2000-10063223	A	20001219		
	DE 2000-10063885	A	20001221		
	DE 2000-10064992	A	20001223		
	WO 2001-EP13915	W	20011128		

OS CASREACT 137:47209; MARPAT 137:47209

L26 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2002:462398 CAPLUS

DN 137:33315

TI Preparation of [1]benzothieno[2,3-d]pyrimidine derivatives as phosphodiesterase V inhibitors and their pharmaceutical formulations containing antithrombotic medicaments.

IN Eggenweiler, Hans-Michael; Eiermann, Volker

PA Merck Patent GmbH, Germany

SO Ger. Offen., 26 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10063221	A1	20020620	DE 2000-10063221	20001219
	WO 2002049649	A2	20020627	WO 2001-EP13913	20011128
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2002026362 A5 20020701 AU 2002-26362 20011128
 PRAI DE 2000-10063221 A 20001219
 DE 2000-10063884 A 20001221
 DE 2000-10064991 A 20001223
 WO 2001-EP13913 W 20011128
 OS CASREACT 137:33315; MARPAT 137:33315

L26 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2002:449449 CAPLUS

DN 137:33318

TI Preparation of pyrimidinylaminothiazoles as tyrosine kinase inhibitors.

IN Bilodeau, Mark T.; Hartman, George D.; Hoffman, Jacob M., Jr.; Lumma, William C., Jr.; Manley, Peter J.; Rodman, Leonard; Sisko, John T.; Smith, Anthony M.; Tucker, Thomas J.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 169 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002045652	A2	20020613	WO 2001-US44573	20011130
	WO 2002045652	A3	20020822		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002137755	A1	20020926	US 2001-990473	20011121
PRAI	US 2000-251006P	P	20001204		
OS	MARPAT 137:33318				

L26 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2002:392237 CAPLUS

DN 136:401651

TI Preparation of fused pyridine derivatives as HMG-CoA reductase inhibitors

IN Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing

PA USA

SO U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 875,218.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002061901	A1	20020523	US 2001-8154	20011204
	US 2002028826	A1	20020307	US 2001-875218	20010606
PRAI	US 2000-211594P	P	20000615		
	US 2001-875218	A2	20010606		
OS	MARPAT 136:401651				

L26 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2002 ACS

AN 2000:156006 CAPLUS

DN 132:317790

TI Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells

AU Kintscher, U.; Kappert, K.; Schmidt, G.; Doerr, G.; Grill, M.;

Wollert-Wulf, B.; Graefe, M.; Fleck, E.; Graf, K.
CS Campus Virchow Klinikum, Charite, Department of Medicine/Cardiology,
Humboldt Universitat Berlin and Deutsches Herzzentrum Berlin, Berlin,
D-13353, Germany
SO European Journal of Pharmacology (2000), 390(1/2), 75-87
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:16:16 ON 02 DEC 2002)

FILE 'REGISTRY' ENTERED AT 15:16:24 ON 02 DEC 2002

L1 122 S ACETAMINOPHEN
L2 0 S ASPRIN
L3 50 S ASPIRIN
E STATIN
L4 1577 S E3 —
L5 29 S VITAMIN C
L6 77 S VITAMIN E
L7 8 S ATORVASTATIN
E STANOL
L8 12 S E3
L9 3 S TIROFIBAN

FILE 'CAPLUS' ENTERED AT 15:25:14 ON 02 DEC 2002

E ATHEROSCLEROSIS
L10 33111 S E3 —
L11 10111 S L1
L12 12 S L11 AND L10
L13 15536 S L3
L14 196 S L13 AND L10
L15 50997 S L4 —
L16 327 S L15 AND L10 >
L17 49222 S L5 —
L18 420 S L17 AND L10 118 utct agnd
L19 26899 S L6 —
L20 800 S L19 AND L10 —
L21 697 S L7
L22 130 S L21 AND L10
L23 8582 S L8
L24 31 S L23 AND L10
L25 198 S L9
L26 10 S L25 AND L10

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:08:00 ON 07 AUG 2003

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:08:06 ON 07 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 AUG 2003 HIGHEST RN 562043-52-1

DICTIONARY FILE UPDATES: 6 AUG 2003 HIGHEST RN 562043-52-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s acetaminophen

L1 0 ACETAMINOOPHEN

=> s acetaminophen

L2 130 ACETAMINOPHEN

=> file ca

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.84	9.05

FILE 'CA' ENTERED AT 14:08:53 ON 07 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 31 Jul 2003 VOL 139 ISS 6
FILE LAST UPDATED: 31 Jul 2003 (20030731/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> e homocystene

E1	3	HOMOCYSTEINYLRIBOSIDE/BI
E2	1	HOMOCYSTEINYLRIBOSIDES/BI
E3	0 -->	HOMOCYSTENE/BI
E4	1	HOMOCYSTENYLGLYCINE/BI
E5	1	HOMOCYSTERATE/BI
E6	1	HOMOCYSTERIC/BI
E7	1	HOMOCYSTERINE/BI
E8	1	HOMOCYSTETIC/BI
E9	4	HOMOCYSTIC/BI
E10	1	HOMOCYSTINATES/BI
E11	888	HOMOCYSTINE/BI
E12	1	HOMOCYSTINECHOLIC/BI

=> e homocysteine

E1	7	HOMOCYSTEINATO/BI
E2	1	HOMOCYSTEINCEHOLIC/BI
E3	7530 -->	HOMOCYSTEINE/BI
E4	1	HOMOCYSTEINE11/BI
E5	1	HOMOCYSTEINECONTAINING/BI
E6	2	HOMOCYSTEINECYSTEINE/BI
E7	1	HOMOCYSTEINEDIH/BI
E8	1	HOMOCYSTEINEDIKETOPIPERAZINE/BI
E9	1	HOMOCYSTEINEE/BI
E10	1	HOMOCYSTEINEHYDROLASE/BI
E11	2	HOMOCYSTEINELESS/BI
E12	2	HOMOCYSTEINEMETHYLTRANSFERASE/BI

=> s e3

L3 7530 HOMOCYSTEINE/BI

=> s l1

L4 0 L1

=> d his

(FILE 'HOME' ENTERED AT 14:08:00 ON 07 AUG 2003)

FILE 'REGISTRY' ENTERED AT 14:08:06 ON 07 AUG 2003

L1	0 S	ACETAMINOOPHEN
L2	130 S	ACETAMINOPHEN

FILE 'CA' ENTERED AT 14:08:53 ON 07 AUG 2003

		E HOMOCYSTENE
		E HOMOCYSTEINE
L3	7530 S	E3
L4	0 S	L1

=> s l2

L5 10702 L2

=> s l5 and l3

L6 9 L5 AND L3

=> d 16 1-9

L6 ANSWER 1 OF 9 CA COPYRIGHT 2003 ACS on STN
AN 138:12504 CA
TI Method for assaying biomolecules and other constituents using indicator
conjugates with synthetic nucleounits in lateral flow, liquid, and dry
chemistry techniques
IN Smith, Jack V.
PA USA
SO U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002182600	A1	20021205	US 2001-829563	20010411
PRAI	US 2001-829563		20010411		

L6 ANSWER 2 OF 9 CA COPYRIGHT 2003 ACS on STN
AN 137:212221 CA
TI Rat toxicologically relevant genes and use in microarrays to evaluate
toxicity of toxic agents
IN Farris, Georgia; Hicken, Samuel H.; Farr, Spencer B.
PA Phase-1 Molecular Toxicology, Inc., USA
SO PCT Int. Appl., 388 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002066682	A2	20020829	WO 2002-US2935	20020129
	WO 2002066682	A3	20021219		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-264933P	P	20010129		
	US 2001-308161P	P	20010726		

L6 ANSWER 3 OF 9 CA COPYRIGHT 2003 ACS on STN
AN 135:14318 CA
TI Method for screening and identifying NSAIDs which induce hepatotoxicity
using differential gene expression
IN Gould-rothberg, Bonnie E.; Dipippo, Vincent A.; Ramseh, Tennore M.;
Gerwein, Robert W.
PA Curagen Corporation, USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI WO 2001038579 A2 20010531 WO 2000-US32049 20001121
 WO 2001038579 A3 20020214
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRAI US 1999-166923P A2 19991122
 US 2000-183531P A2 20000218
 US 2000-717321 A2 20001120

L6 ANSWER 4 OF 9 CA COPYRIGHT 2003 ACS on STN
 AN 134:96219 CA
 TI Method for identifying toxic agents in liver tissues using differential
 gene expression
 IN Gould-Rothberg, Bonnie E.; Dipippo, Vincent A.; Milroy, Laura; Daniels,
 Kellye K.
 PA Curagen Corporation, USA
 SO PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002609	A2	20010111	WO 2000-US40292	20000630
	WO 2001002609	A3	20020912		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1255857	A2	20021113	EP 2000-960121	20000630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003518365	T2	20030610	JP 2001-508380	20000630
PRAI	US 1999-142335P	P	19990702		
	US 2000-607539	A2	20000629		
	WO 2000-US40292	W	20000630		

L6 ANSWER 5 OF 9 CA COPYRIGHT 2003 ACS on STN
 AN 133:54617 CA
 TI Mutagenicity of 80 chemicals in Escherichia coli tester strains IC203,
 deficient in OxyR, and its oxyR+ parent WP2 uvrA/pKM101: detection of 31
 oxidative mutagens
 AU Martinez, A.; Urios, A.; Blanco, M.
 CS Fundacion Valenciana de Investigaciones Biomedicas, Instituto de
 Investigaciones Citologicas, Valencia, 46010, Spain
 SO Mutation Research (2000), 467(1), 41-53
 CODEN: MUREAV; ISSN: 0027-5107
 PB Elsevier Science B.V.
 DT Journal
 LA English
 RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 9 CA COPYRIGHT 2003 ACS on STN
AN 132:121896 CA
TI Effect of methionine supplementation on endothelial function, plasma
homocysteine, and lipid peroxidation
AU McAuley, Daniel F.; Hanratty, Colm G.; McGurk, Colm; Nugent, Ailish G.;
Johnston, G. Dennis
CS The Queen's University of Belfast, Belfast, BT9 7BL, UK
SO Journal of Toxicology, Clinical Toxicology (1999), 37(4), 435-440
CODEN: JTCTDW; ISSN: 0731-3810
PB Marcel Dekker, Inc.
DT Journal
LA English
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 9 CA COPYRIGHT 2003 ACS on STN
AN 121:170568 CA
TI The use of nitric oxide-delivering compounds for the treatment or
prevention of alcoholic liver injury
IN Nanji, Amin; Stamler, Jonathan; Loscalzo, Joseph
PA Brigham and Women's Hospital, USA; New England Deaconess Hospital
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9416740	A1	19940804	WO 1994-US970	19940127
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9462327	A1	19940815	AU 1994-62327	19940127
PRAI	US 1993-12135		19930129		
	WO 1994-US970		19940127		

L6 ANSWER 8 OF 9 CA COPYRIGHT 2003 ACS on STN
AN 113:55233 CA
TI Amino acid analysis of physiological fluids by high-performance liquid
chromatography with phenylisothiocyanate derivatization and comparison
with ion-exchange chromatography
AU Davey, John F.; Ersser, Roger S.
CS Dep. Clin. Biochem., Inst. Child Health, London, WC1N 3JH, UK
SO Journal of Chromatography (1990), 528(1), 9-23
CODEN: JOCRAM; ISSN: 0021-9673
DT Journal
LA English
OS CASREACT 113:55233

L6 ANSWER 9 OF 9 CA COPYRIGHT 2003 ACS on STN
AN 95:73129 CA
TI In vitro interactions of sulfur-containing compounds with the hepatic
mixed-function oxidase system in mice: effects on paracetamol activation
and covalent binding
AU Tredger, J. Michael; Smith, Heather M.; Davis, Michael; Williams, Roger
CS Med. Sch., King's Coll. Hosp., London, SE5 9RX, UK
SO Toxicology and Applied Pharmacology (1981), 59(1), 111-24
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
11.88	20.93

FILE 'CAPLUS' ENTERED AT 14:11:10 ON 07 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2003 VOL 139 ISS 6
FILE LAST UPDATED: 6 Aug 2003 (20030806/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 14:08:00 ON 07 AUG 2003)

FILE 'REGISTRY' ENTERED AT 14:08:06 ON 07 AUG 2003

L1 0 S ACETAMINOOPHEN
L2 130 S ACETAMINOPHEN

FILE 'CA' ENTERED AT 14:08:53 ON 07 AUG 2003

E HOMOCYSTENE
E HOMOCYSTEINE
L3 7530 S E3
L4 0 S L1
L5 10702 S L2
L6 9 S L5 AND L3

FILE 'CAPLUS' ENTERED AT 14:11:10 ON 07 AUG 2003

=> s l2 and l3
10725 L2
7891 HOMOCYSTEINE/BI
L7 9 L2 AND L3

=> e plaque

E1 2 PLAQU/BI
E2 2 PLAQUALBUMIN/BI
E3 21528 --> PLAQUE/BI
E4 1 PLAQUEASSAY/BI
E5 21 PLAQUED/BI
E6 1 PLAQUEE/BI
E7 23 PLAQUEFORMING/BI
E8 1 PLAQUEFREE/BI
E9 4 PLAQUEING/BI

E10 1 PLAQUEINHIBITION/BI
E11 3 PLAQUELIKE/BI
E12 8 PLAQUEMINE/BI

=> s e3

L8 21528 PLAQUE/BI

=> s l8 and l3

7891 HOMOCYSTEINE/BI
L9 43 L8 AND L3

=> d 19 10-43

L9 ANSWER 10 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:629512 CAPLUS
DN 137:350081
TI Patients with atherosclerotic vascular disease: How low should plasma
homocyst(e)ine Levels go?
AU Spence, J. David
CS Stroke Prevention and Atherosclerosis Research Centre,
Siebens-Drake/Roberts Research Institute, London, ON, Can.
SO American Journal of Cardiovascular Drugs (2001), 1(2), 85-89
CODEN: AJCDDJ; ISSN: 1175-3277
PB Adis International Ltd.
DT Journal; General Review
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:532759 CAPLUS
DN 137:292675
TI Association of plasma **homocysteine** concentration with
atherosclerotic carotid plaques and lacunar infarction
AU Sasaki, Tsutomu; Watanabe, Manabu; Nagai, Yoji; Hoshi, Taku; Takasawa,
Masashi; Nukata, Masaru; Taguchi, Akihiko; Kitagawa, Kazuo; Kinoshita,
Naokazu; Matsumoto, Masayasu
CS Department of Internal Medicine and Therapeutics, Graduate School of
Medicine, Osaka University, Osaka, Japan
SO Stroke (2002), 33(6), 1493-1496
CODEN: SJCCA7; ISSN: 0039-2499
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:499510 CAPLUS
DN 137:276953
TI **Homocysteine** and the stage of atherosclerotic disease: A study
in patients suffering from clinically silent and clinically manifest
atherosclerotic disease
AU Pasterkamp, G.; Algra, A.; De Jaegere, D. E.; Banga, J. D.; van der Graaf,
Y.; Grobbee, P. P. T.
CS Utrecht University Hospital, Utrecht, 3508 GA, Neth.
SO European Journal of Clinical Investigation (2002), 32(5), 309-315
CODEN: EJCIB8; ISSN: 0014-2972
PB Blackwell Science Ltd.
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 13 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:452738 CAPLUS
 DN 137:260731
 TI Pathogenesis of atherosclerosis: a multifactorial process
 AU Singh, Raja B.; Mengi, Sushma A.; Xu, Yan-Jun; Arneja, Amarjit S.; Dhalla, Naranjan S.
 CS Institute of Cardiovascular Sciences, Departments of Physiology and Internal Medicine, Faculty of Medicine, St. Boniface General Hospital Research Centre, University of Manitoba, Winnipeg, MB, Can.
 SO Experimental & Clinical Cardiology (2002), 7(1), 40-53
 CODEN: ECCAF7; ISSN: 1205-6626
 PB Pulsus Group Inc.
 DT Journal; General Review
 LA English
 RE.CNT 139 THERE ARE 139 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:430206 CAPLUS
 DN 137:231180
 TI Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis
 AU Wallberg-Jonsson, Solveig; Cvetkovic, Jasmina Trifunovic; Sundqvist, Karl-Gosta; Lefvert, Ann Kari; Rantapaa-Dahlqvist, Solbritt
 CS Departments of Rheumatology and Clinical Immunology, University Hospital, Umea, S-901 85, Swed.
 SO Journal of Rheumatology (2002), 29(5), 875-882
 CODEN: JRHUA9; ISSN: 0315-162X
 PB Journal of Rheumatology Publishing Co. Ltd.
 DT Journal
 LA English
 RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 15 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:357090 CAPLUS
 DN 137:260667
 TI Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid
 AU Teunissen, C. E.; de Vente, J.; Steinbusch, H. W. M.; De Bruijn, C.
 CS European Graduate School of Neuroscience (Euron), Department of Psychiatry and Neuropsychology, Universiteit Maastricht, Maastricht, 6200 MD, Neth.
 SO Neurobiology of Aging (2002), 23(4), 485-508
 CODEN: NEAGDO; ISSN: 0197-4580
 PB Elsevier Science Inc.
 DT Journal; General Review
 LA English
 RE.CNT 316 THERE ARE 316 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 16 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:290025 CAPLUS
 DN 137:31510
 TI Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid .beta.-protein
 AU Sai, Xiaorei; Kawamura, Yuuki; Kokame, Koichi; Yamaguchi, Haruyasu; Shiraishi, Hirohisa; Suzuki, Ryo; Suzuki, Toshiharu; Kawaichi, Masashi; Miyata, Toshiyuki; Kitamura, Toshio; De Strooper, Bart; Yanagisawa, Katsuhiko; Komano, Hiroto

CS Department of Dementia Research, National Institute for Longevity
Sciences, Obu, 474-8522, Japan
SO Journal of Biological Chemistry (2002), 277(15), 12915-12920
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 17 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:705796 CAPLUS
DN 135:357256
TI Dietary supplementation with methionine and **homocysteine**
promotes early atherosclerosis but not **plaque** rupture in
ApoE-deficient mice
AU Zhou, Ji; Moller, Jan; Danielsen, Carl C.; Bentzon, Jacob; Ravn, Hanne B.;
Austin, Richard C.; Falk, Erling
CS Department of Cardiology and the Institute of Experimental Clinical
Research, Aarhus University Hospital (Skejby), Aarhus University, Aarhus,
Den.
SO Arteriosclerosis, Thrombosis, and Vascular Biology (2001), 21(9),
1470-1476
CODEN: ATVBFA; ISSN: 1079-5642
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 18 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:688030 CAPLUS
DN 136:68032
TI **Homocysteine** plasma levels in young patients with coronary
artery disease. Relation to history of acute myocardial infarction and
anatomical extent of disease
AU Nikfardjam, M.; Graf, S.; Hornykewycz, S.; Zorn, G.; Huber-Beckmann, R.;
Wojta, J.; Huber, K.
CS Department of Cardiology, University of Vienna, Vienna, A-1090, Austria
SO Thrombosis Research (2001), 103(Suppl. 1), S35-S39
CODEN: THBRAA; ISSN: 0049-3848
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:627543 CAPLUS
DN 136:197624
TI Vascular endothelium - functions, its disorders and clinical modification
AU Lesniak, Wiktorja; Kolasinska-Kloch, Wladyslawa; Kiec, Beata
CS Inst. Kardiol., II Klinika Kardiol. Collegium Medicum, UJ, Krakow, 31-501,
Pol.
SO Folia Medica Cracoviensia (2001), 42(1-2), 5-14
CODEN: FMCRAW; ISSN: 0015-5616
PB Wydawnictwo Oddzialu Polskiej Akademii Nauk, Krakow
DT Journal; General Review
LA Polish

L9 ANSWER 20 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:549624 CAPLUS

DN 136:132357
TI New non-lipidic biological markers of atherosclerosis
AU Beaudeau, Jean-Louis; Jacob, Nelly; Giral, Philippe; Foglietti,
Marie-Jose; Bruckert, Eric
CS Service de Biochimie C, Federation de Biochimie, Groupe Hospitalier
Pitie-Salpetriere, Paris, 75651, Fr.
SO Annales de Medecine Interne (2001), 152(3), 169-179
CODEN: AMDIBO; ISSN: 0003-410X
PB Masson Editeur
DT Journal; General Review
LA French
RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 21 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:497603 CAPLUS
DN 136:245439
TI Oxidative modification of low density lipoprotein and atherosclerosis
induced by hyperhomocysteinemia following administration of high doses of
methionine
AU Chen, Jingkai; Zhou, Liaojun; Zhao, Qiuliang; Chen, Manqing
CS The 101st Hospital of PLA, Wuxi, 214044, Peop. Rep. China
SO Jiefangjun Yixue Zazhi (2001), 26(5), 327-329
CODEN: CFCHBN; ISSN: 0577-7402
PB Jenminjun Chubanshe
DT Journal
LA Chinese

L9 ANSWER 22 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:205413 CAPLUS
DN 134:365045
TI Hyperhomocysteinemia enhances vascular inflammation and accelerates
atherosclerosis in a murine model
AU Hofmann, Marion A.; Lalla, Evanthia; Lu, Yan; Gleason, Michelle Ryu; Wolf,
Bonnie M.; Tanji, Nozomu; Ferran, Luis J., Jr.; Kohl, Brigitte; Rao,
Vijay; Kisiel, Walter; Stern, David M.; Schmidt, Ann Marie
CS College of Physicians and Surgeons, Columbia University, New York, NY,
10032, USA
SO Journal of Clinical Investigation (2001), 107(6), 675-683
CODEN: JCINAO; ISSN: 0021-9738
PB American Society for Clinical Investigation
DT Journal
LA English
RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 23 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:902995 CAPLUS
DN 134:324475
TI Serum ferritin and C282Y mutation of the hemochromatosis gene as
predictors of asymptomatic carotid atherosclerosis in a community
population
AU Rossi, Enrico; McQuillan, Brendan M.; Hung, Joseph; Thompson, Peter L.;
Kuek, Conchita; Beilby, John P.
CS Department of Clinical Biochemistry, PathCentre, Queen Elizabeth II
Medical Centre, Nedlands, 6009, Australia
SO Stroke (2000), 31(12), 3015-3020
CODEN: SJCCA7; ISSN: 0039-2499
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:439147 CAPLUS
 DN 133:162212
 TI Atherosclerosis risk factors: the possible role of **homocysteine**
 AU Choy, Patrick C.; Mymin, David; Zhu, Quansheng; Dakshinamurti, K.; Karmin, O.
 CS The Lipid Research Group, Faculty of Medicine, University of Manitoba, Winnipeg, MB, R3E 0W3, Can.
 SO Molecular and Cellular Biochemistry (2000), 207(1&2), 143-148
 CODEN: MCBIB8; ISSN: 0300-8177
 PB Kluwer Academic Publishers
 DT Journal; General Review
 LA English
 RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 25 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:423049 CAPLUS
 DN 133:133547
 TI Lack of association between carotid intima-media thickness and methylenetetrahydrofolate reductase gene polymorphism or serum **homocysteine** in non-insulin-dependent diabetes mellitus
 AU Mazza, Alfredo; Motti, Corradino; Nulli, Angela; Marra, Giampiero; Gnasso, Agostino; Pastore, Anna; Federici, Giorgio; Cortese, Claudio
 CS Department of Geriatrics and Metabolism, The Second University, Naples, Italy
 SO Metabolism, Clinical and Experimental (2000), 49(6), 718-723
 CODEN: METAAJ; ISSN: 0026-0495
 PB W. B. Saunders Co.
 DT Journal
 LA English
 RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:141463 CAPLUS
 DN 132:317789
 TI What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 $\mu\text{mol/L}$
 AU Hackam, Daniel G.; Peterson, John C.; Spence, J. David
 CS Stroke Prevention & Atherosclerosis Research Centre, Siebens-Drake/Robarts Research Institute, London, ON, N6G 2V2, Can.
 SO American Journal of Hypertension (2000), 13(1, Pt. 1), 105-110
 CODEN: AJHYE6; ISSN: 0895-7061
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 27 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:712287 CAPLUS
 DN 132:249111
 TI **Homocysteine** as independent risk factor for atherosclerosis
 AU Hasegawa, Takashi
 CS Hukagawa Public Health Cent., Tokyo, Japan
 SO Domyaku Koka (1999), 26(9,10), 249-257
 CODEN: DOMKDM; ISSN: 0386-2682
 PB Nippon Domyaku Koka Gakkai

DT Journal; General Review
LA Japanese

L9 ANSWER 28 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:285586 CAPLUS
DN 131:114406
TI **Homocysteine**-induced pathogenic mechanisms of vascular disease
AU Atanasiu, V.; Stanciu, B.; Trutia, E.
CS Department of Biochemistry, "Carol Davilla" University of Medicine and
Pharmacy, Bucharest, Rom.
SO Journal of Medicine and Biochemistry (1999), 3(1), 1-8
CODEN: JMBCFV; ISSN: 1453-1321
PB Enzymology and Biotechnology Research Center
DT Journal; General Review
LA English

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 29 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:37289 CAPLUS
DN 130:221427
TI Hyperhomocysteinemia induces elastolysis in minipig arteries: structural
consequences, arterial site specificity and effect of captopril-
hydrochlorothiazide
AU Charpiot, Philippe; Bescond, Anne; Augier, Thierry; Chareyre, Corinne;
Fraterno, Marc; Rolland, Pierre-Henri; Garcon, Danielle
CS DRED EA 2195, INSERM CFJ 94-01, Laboratory of Biochemistry, School of
Pharmacy, Marseille, Fr.
SO Matrix Biology (1998), 17(8-9), 559-574
CODEN: MTBOEC; ISSN: 0945-053X
PB Gustav Fischer Verlag
DT Journal
LA English

RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 30 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:222271 CAPLUS
DN 129:3457
TI Reduction-oxidation (redox) and vascular tissue level of homocyst(e)ine in
human coronary atherosclerotic lesions and role in extracellular matrix
remodeling and vascular tone
AU Tyagi, Suresh C.; Smiley, Lane M.; Mujumdar, Vibhas S.; Clonts, Brian;
Parker, Janet L.
CS Department of Physiology and Biophysics, University of Mississippi Medical
Center, Jackson, MS, 39216-4505, USA
SO Molecular and Cellular Biochemistry (1998), 181(1&2), 107-116
CODEN: MCBIB8; ISSN: 0300-8177
PB Kluwer Academic Publishers
DT Journal
LA English

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 31 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:41594 CAPLUS
TI Myocardial infarction in a 35-year-old man with homocysteinemia, high
plasminogen activator inhibitor activity, and resistance to activated
protein C
AU Glueck, C. J.; Fontaine, Robert N.; Gupta, Arun; Alasmi, Mahmood
CS Cholesterol Center, Jewish Hospital, Cincinnati, OH, 45229, USA
SO Metabolism, Clinical and Experimental (1997), 46(12), 1470-1472

CODEN: META AJ; ISSN: 0026-0495

PB W. B. Saunders Co.

DT Journal

LA English

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 32 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:572343 CAPLUS
DN 125:241490
TI Purification, kinetic properties, and cDNA cloning of mammalian betaine-
homocysteine methyltransferase
AU Garrow, Timothy A.
CS Dep. Food Sci. Human Nutrition, Univ. Illinois, Urbana, IL, 61801, USA
SO Journal of Biological Chemistry (1996), 271(37), 22831-22838
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English

L9 ANSWER 33 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:147789 CAPLUS
DN 124:197258
TI Technetium-99m-labeled peptides for imaging
IN Dean, Richard T.; Buttram, Scott; McBride, William; Lister-James, John;
Civitello, Edgar R.
PA Diatech, Inc., USA
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 44

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9533498	A1	19951214	WO 1995-US7017	19950601
	W: AU, BR, CA, CN, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5997844	A	19991207	US 1994-253678	19940603
	AU 9527783	A1	19960104	AU 1995-27783	19950601
	AU 697048	B2	19980924		
	EP 762901	A1	19970319	EP 1995-922946	19950601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10501241	T2	19980203	JP 1995-501223	19950601
PRAI	US 1994-253678	A	19940603		
	US 1991-653012	B2	19910208		
	US 1993-92355	A2	19930715		
	WO 1995-US7017	W	19950601		
OS	MARPAT 124:197258				

L9 ANSWER 34 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:38230 CAPLUS
DN 124:169544
TI Technetium-99m-labeled peptides as scintigraphic imaging agents
IN Dean, Richard T.; Lister-James, John; McBride, William
PA Diatech, Inc., USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 44

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----

PI WO 9529708 A1 19951109 WO 1995-US5340 19950501
W: AU, CA, CN, JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
CA 2189420 AA 19951109 CA 1995-2189420 19950501
AU 9524633 A1 19951129 AU 1995-24633 19950501
AU 704460 B2 19990422
EP 772459 A1 19970514 EP 1995-918875 19950501
EP 772459 B1 20030319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
CN 1152881 A 19970625 CN 1995-193737 19950501
CN 1087955 B 20020724
JP 09512555 T2 19971216 JP 1995-528440 19950501
AT 234639 E 20030415 AT 1995-918875 19950501
ZA 9503494 A 19960628 ZA 1995-3494 19950502
PRAI US 1994-236402 A2 19940502
WO 1995-US5340 W 19950501
OS MARPAT 124:169544

L9 ANSWER 35 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:189059 CAPLUS
DN 118:189059
TI Fibrin, lipoprotein(a), plasmin interactions: a model linking thrombosis and atherogenesis
AU Harpel, Peter C.; Borth, Wolfgang
CS Dep. Med., Mt. Sinai Med. Cent., New York, NY, 10029, USA
SO Annals of the New York Academy of Sciences (1992), 667(Plasminogen Activation in Fibrinolysis, in Tissue Remodeling, and in Development), 233-8
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal
LA English

L9 ANSWER 36 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:400320 CAPLUS
DN 117:320
TI Antiretroviral activity of mechanism-based irreversible inhibitors of S-adenosylhomocysteine hydrolase
AU Prakash, Nellikunja J.; Davis, Gregory F.; Jarvi, Esa T.; Edwards, Michael L.; McCarthy, James R.; Bowlin, Terry L.
CS Marion Merrell Dow Res. Inst., Cincinnati, OH, 45215, USA
SO Life Sciences (1992), 50(19), 1425-35
CODEN: LIFSAK; ISSN: 0024-3205
DT Journal
LA English

L9 ANSWER 37 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1990:470757 CAPLUS
DN 113:70757
TI 2-Methylpropyl ester of 3-(adenin-9-yl)-2-hydroxypropanoic acid. Mechanism of antiviral action in vaccinia virus-infected L929 cells
AU Votruba, Ivan; Hasobe, Masahide; Holy, Antonin; Borchardt, Ronald T.
CS Dep. Pharm. Chem., Univ. Kansas, Lawrence, KS, 66045, USA
SO Biochemical Pharmacology (1990), 39(10), 1573-80
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English

L9 ANSWER 38 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:608758 CAPLUS
DN 111:208758
TI Elucidation of the mechanism by which **homocysteine** potentiates the anti-vaccinia virus effects of the S-adenosylhomocysteine hydrolase

inhibitor 9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)adenine
AU Hasobe, Masahide; McKee, James G.; Ishii, Hiroaki; Cools, Marina;
Borchardt, Ronald T.; De Clercq, Erik
CS Dep. Pharm. Chem., Univ. Kansas, Lawrence, KS, 66045, USA
SO Molecular Pharmacology (1989), 36(3), 490-6
CODEN: MOPMA3; ISSN: 0026-895X
DT Journal
LA English

L9 ANSWER 39 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1984:185387 CAPLUS
DN 100:185387
TI Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and
of vaccinia virus multiplication in mouse L929 cells
AU Borchardt, Ronald T.; Keller, Bradley T.; Patel-Thombre, Usha
CS Dep. Biochem., Univ. Kansas, Lawrence, KS, 66045, USA
SO Journal of Biological Chemistry (1984), 259(7), 4353-8
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English

L9 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1983:27509 CAPLUS
DN 98:27509
TI Immunosuppressive effects of the S-adenosylhomocysteine hydrolase
inhibitor, 3-deazaadenosine
AU Medzihradsky, J. L.; Zimmerman, T. P.; Wolberg, G.; Elion, G. B.
CS Wellcome Res. Lab., Research Triangle Park, NC, 27709, USA
SO Journal of Immunopharmacology (1982), 4(1-2), 29-41
CODEN: JOIMD6; ISSN: 0163-0571
DT Journal
LA English

L9 ANSWER 41 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:470495 CAPLUS
DN 91:70495
TI Analogs of S-adenosyl-L-**homocysteine** as inhibitors of viral mRNA
methyltransferases
AU Borchardt, Ronald T.; Pugh, Charles S. G.
CS Dep. Biochem., Univ. Kansas, Lawrence, KS, 66044, USA
SO Developments in Neuroscience (Amsterdam) (1979), Volume Date 1978,
5(Transmethylation), 197-206
CODEN: DNEUD5; ISSN: 0165-7003
DT Journal; General Review
LA English

L9 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:502683 CAPLUS
DN 89:102683
TI Sinefungin, a potent inhibitor of virion mRNA(guanine-7-)-
methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viral
multiplication
AU Pugh, Charles S. G.; Borchardt, Ronald T.; Stone, Henry O.
CS Dep. Biochem., Univ. Kansas, Lawrence, KS, USA
SO Journal of Biological Chemistry (1978), 253(12), 4075-7
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English

L9 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:183871 CAPLUS
DN 88:183871

TI Anti-inflammatory drugs in experimental atherosclerosis. Part 3.
Evaluation of the atherogenicity of homocystine in rabbits
AU Makheja, A. N.; Bombard, A. T.; Randazzo, R. L.; Bailey, J. M.
CS Dep. Biochem., George Washington Univ. Sch. Med., Washington, DC, USA
SO Atherosclerosis (Shannon, Ireland) (1978), 29(1), 105-12
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English

=> d 19 43 all

L9 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:183871 CAPLUS
DN 88:183871
TI Anti-inflammatory drugs in experimental atherosclerosis. Part 3.
Evaluation of the atherogenicity of homocystine in rabbits
AU Makheja, A. N.; Bombard, A. T.; Randazzo, R. L.; Bailey, J. M.
CS Dep. Biochem., George Washington Univ. Sch. Med., Washington, DC, USA
SO Atherosclerosis (Shannon, Ireland) (1978), 29(1), 105-12
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English
CC 3-5 (Biochemical Interactions)
Section cross-reference(s): 1
AB Dietary administration of DL-homocysteine thiolactone-HCl
[6038-19-3], DL-homocystine [870-93-9], or DL-homocysteic acid
[504-33-6] to rabbits for 12 wk only slightly increased plasma levels of
homocystine, did not affect serum cholesterol [57-88-5] levels, did not
alter the pattern of collagen-induced platelet aggregation, and induced no
atherosclerotic plaque formation. The absence of pathol.
effects was consistent with the rapid clearance of i.v. injected
homocystine from rabbit plasma. Thus, the rabbit is not an acceptable
exptl. model for study of the thromboatherogenic effects of homocystine
reported for humans and some other animals.
ST homocystine atherogenicity rabbit; cholesterol blood homocystine; platelet
aggregation homocystine
IT Blood platelet
(aggregation of, homocystine effect on)
IT Atherosclerosis
(from homocystine, in rabbit)
IT 504-33-6 870-93-9 6038-19-3
RL: PRP (Properties)
(atherogenicity of, in rabbit)
IT 57-88-5, biological studies
RL: BIOL (Biological study)
(of blood, homocystine effect on)

=> d his

(FILE 'HOME' ENTERED AT 14:08:00 ON 07 AUG 2003)

FILE 'REGISTRY' ENTERED AT 14:08:06 ON 07 AUG 2003

L1 0 S ACETAMINOOPHEN
L2 130 S ACETAMINOPHEN

FILE 'CA' ENTERED AT 14:08:53 ON 07 AUG 2003

E HOMOCYSTENE
E HOMOCYSTEINE
L3 7530 S E3
L4 0 S L1

L5 10702 S L2
L6 9 S L5 AND L3

FILE 'CAPLUS' ENTERED AT 14:11:10 ON 07 AUG 2003

L7 9 S L2 AND L3
E PLAQUE
L8 21528 S E3
L9 43 S L8 AND L3

=> s l5 and l8
10725 L2
L10 6 L5 AND L8

=> d k10 1-6
'K10' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields

KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):bib

L10 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:777648 CAPLUS
DN 137:257659
TI Therapeutic combinations for cardiovascular and inflammatory indications
IN Seibert, Karen; Keller, Bradley T.; Isakson, Peter C.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002078625	A2	20021010	WO 2002-US9185	20020327
	WO 2002078625	A3	20030313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-279239P	P	20010328		

L10 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:32862 CAPLUS
DN 136:97716
TI Potentiation of the immunotoxicity of ethanol by acetaminophen in mice
AU Kim, Joung-Hoon; Park, Joung-Suk
CS Department of Newly Developed Drugs, Professional Graduate School of Oriental Medicine, Wonkwang University, Chunbuk, 570-749, S. Korea
SO International Immunopharmacology (2002), 2(1), 15-24
CODEN: IINMBA; ISSN: 1567-5769
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:227470 CAPLUS
DN 132:255811
TI Fast dissolving orally consumable films
IN Leung, Sau-Hung Spence; Leone, Robert S.; Kumar, Lori Dee; Kulkarni, Neema; Sorg, Albert F.

PA Warner-Lambert Company, USA
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018365	A2	20000406	WO 1999-US22115	19990923
	WO 2000018365	A3	20001116		
	W:	AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2003054034	A1	20030320	US 1999-395104	19990914
	US 6596298	B2	20030722		
	CA 2339353	AA	20000406	CA 1999-2339353	19990923
	AU 9960593	A1	20000417	AU 1999-60593	19990923
	EP 1115372	A2	20010718	EP 1999-969668	19990923
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002525306	T2	20020813	JP 2000-571886	19990923
	EE 200100186	A	20020815	EE 2001-186	19990923
	NO 2001001476	A	20010322	NO 2001-1476	20010322
	US 2001022964	A1	20010920	US 2001-836474	20010418
	US 2003008008	A1	20030109	US 2002-81018	20020221
PRAI	US 1998-101798P	P	19980925		
	US 1999-395104	A3	19990914		
	WO 1999-US22115	W	19990923		

L10 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:715148 CAPLUS
DN 130:119083
TI Effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome
AU Crocker, John F. S.; Digout, Sharon C.; Lee, Spencer H.; Rozee, Ken R.; Renton, Ken; Field, Chris A.; Acott, Philip; Murphy, Mary G.
CS Department of Pediatrics, Dalhousie University and the Izaak Walton Killam-Grace Health Centre, Halifax, NS, Can.
SO Clinical and Investigative Medicine (1998), 21(4-5), 192-202
CODEN: CNVMDL; ISSN: 0147-958X
PB Canadian Medical Association
DT Journal
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:34823 CAPLUS
DN 124:97765
TI Controlled-release formulations coated with aqueous dispersions of ethylcellulose
IN Oshlack, Benjamin; Chasin, Mark; Pedi, Frank Jr.
PA Euroceltique, S.A., Luxembourg
SO U.S., 47 pp. Cont.-in-part of U.S. 5,273,760.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5472712	A	19951205	US 1993-81618	19930623
	US 5273760	A	19931228	US 1991-814111	19911224
	IN 173974	A	19940820	IN 1992-CA121	19920221
	ZA 9201366	A	19921230	ZA 1992-1366	19920225
	CA 2061824	AA	19930625	CA 1992-2061824	19920225
	CA 2061824	C	19990406		
	IL 101080	A1	19961205	IL 1992-101080	19920227
	JP 07165609	A2	19950627	JP 1992-71808	19920330
	JP 3061474	B2	20000710		
	AT 196079	E	20000915	AT 1992-106519	19920415
	ES 2152221	T3	20010201	ES 1992-106519	19920415
	IN 173298	A	19940326	IN 1992-CA462	19920629
	BR 9202982	A	19930629	BR 1992-2982	19920731
	AU 9230024	A1	19930701	AU 1992-30024	19921208
	AU 652871	B2	19940908		
	NO 9205016	A	19930625	NO 1992-5016	19921223
	EP 630646	A1	19941228	EP 1994-109115	19940614
	EP 630646	B1	20020731		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	EP 1203581	A2	20020508	EP 2001-130255	19940614
	EP 1203581	A3	20021211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI				
	AT 221375	E	20020815	AT 1994-109115	19940614
	ES 2180552	T3	20030216	ES 1994-109115	19940614
	CA 2125904	AA	19941224	CA 1994-2125904	19940615
	AU 9464846	A1	19950119	AU 1994-64846	19940620
	AU 680491	B2	19970731		
	FI 9403022	A	19941224	FI 1994-3022	19940622
	NO 9402382	A	19941227	NO 1994-2382	19940622
	JP 07138189	A2	19950530	JP 1994-142012	19940623
	JP 08175977	A2	19960709	JP 1994-221510	19940916
	IN 178679	A	19970607	IN 1994-CA900	19941031
	US 5968551	A	19991019	US 1995-508246	19950727
	IN 182215	A	19990206	IN 1996-CA1452	19960813
	AU 9743687	A1	19980122	AU 1997-43687	19971031
	AU 704524	B2	19990429		
	HK 1005686	A1	20010209	HK 1998-104870	19980604
	US 6294195	B1	20010925	US 1999-390719	19990907
	US 2002081333	A1	20020627	US 2001-891882	20010626
	US 6572885	B2	20030603		
PRAI	US 1991-814111	A2	19911224		
	US 1992-826084	A2	19920127		
	US 1993-81618	A	19930623		
	US 1993-86248	B2	19930701		
	US 1993-97558	A2	19930727		
	US 1993-133503	B1	19931007		
	EP 1994-109115	A3	19940614		
	IN 1994-CA455	A1	19940615		
	US 1995-508246	A1	19950727		
	US 1999-390719	A1	19990907		

L10 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1981:400387 CAPLUS

DN 95:387

TI "In vivo" effects of acetylsalicylic acid and two ether derived compounds on primary immune response and lymphoblastic transformation

AU Barasoain, I.; Rojo, J. M.; Portoles, A.

CS Inst. Immunol. Biol. Microbiana, CSIC, Madrid, Spain

SO Immunopharmacology (1980), 2(4), 293-300

CODEN: IMMUDP; ISSN: 0162-3109

DT Journal

LA English

=> d 110 6 all

L10 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1981:400387 CAPLUS

DN 95:387

TI "In vivo" effects of acetylsalicylic acid and two ether derived compounds on primary immune response and lymphoblastic transformation

AU Barasoain, I.; Rojo, J. M.; Portoles, A.

CS Inst. Immunol. Biol. Microbiana, CSIC, Madrid, Spain

SO Immunopharmacology (1980), 2(4), 293-300

CODEN: IMMUDP; ISSN: 0162-3109


DT Journal

LA English

CC 1-5 (Pharmacodynamics)

Section cross-reference(s): 15

GI



AB The in vivo effects of acetylsalicylic acid (I) [50-78-2], Benorilate [5003-48-5], (II) and Eterilate [62992-61-4] (III) on lymphoblastic transformation and primary immune response were studied in mice. The humoral response in Benorilate- and Eterilate-treated mice was 40-50% lower than that of the controls, whereas in I-treated mice the response was only 25% inhibited. The no. of Ig synthesizing cells was neither reduced by I nor by its derivs., although indomethacin treatments (used for comparative purposes) inhibited by 40% the no. of direct plaque-forming cells on the days tested. Mitogen-induced proliferation of spleen lymphocytes was also inhibited in the treated mice; these inhibitions were negligible in the case of cells from I treated mice activated by concanavalin A and slight in cells from Benorilate-treated mice activated by bacterial lipopolysaccharide. When lymphocytes from drug-treated animals were further cultured in the presence of the same drug, a variable inhibition of mitogen-induced proliferation was obsd. These different in vivo effects of I and the 2 ether derivs. and indomethacin may be due to a distinct action on diverse lymphocyte subpopulations altering their cellular collaborative interactions or modifying the prostaglandin availability.

ST acetylsalicylate deriv immune response lymphoblast

IT Immunosuppression

(by acetylsalicylate and its derivs.)

IT Lymphoblast

(transformation of, acetylsalicylate and its derivs. effect on)

IT 50-78-2 5003-48-5 62992-61-4

RL: BIOL (Biological study)
(immune response and lymphoblast transformation response to)

=> d 110 4 all

L10 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:715148 CAPLUS
DN 130:119083
TI Effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome
AU Crocker, John F. S.; Digout, Sharon C.; Lee, Spencer H.; Rozee, Ken R.; Renton, Ken; Field, Chris A.; Acott, Philip; Murphy, Mary G.
CS Department of Pediatrics, Dalhousie University and the Izaak Walton Killam-Grace Health Centre, Halifax, NS, Can.
SO Clinical and Investigative Medicine (1998), 21(4-5), 192-202
CODEN: CNVMDL; ISSN: 0147-958X
PB Canadian Medical Association
DT Journal
LA English
CC 1-4 (Pharmacology)
AB To det. the effects of acetylsalicylic acid (ASA) and acetaminophen on mortality due to influenza B infection in neonatal and weanling mice, as well as any synergistic, antagonistic or indifferent effects of the combined antipyretic and virus on mortality in mice pre-treated with low doses of an industrial surfactant, Toximul MP8, which has been shown to reproduce many of the features of Reye's syndrome. In vitro studies were done to det. whether ASA or acetaminophen altered the normal, interferon-mediated antiviral responses of mammalian cells. The involvement of ASA or other commonly used xenobiotics in the induction of Reye's syndrome following virus illness has not been resolved; to do so, and to elucidate the underlying metabolic mechanism, requires these studies in an animal model. Prospective animal study. Newborn (945) and weanling (840) Swiss white mice, divided into 12 subgroups. Some groups received Toximul MP8 before inoculation with a dose of mouse-adapted human influenza B that produces 30% mortality (LD30); after infection, each subgroup received either placebo, ASA or acetaminophen. Mortality counts were taken daily. The in vitro effects of the antipyretics on interferon response were detd. using std. virol. techniques. Mortality, analyzed by survival curves (log rank test) or cumulative daily mortality (.chi.2 anal.). **Plaque-reducing dose (PRD50)** was used to det. the outcome of the in vitro analyses. In neonatal mice, only subgroups given combined treatment with acetaminophen and Toximul MP8 had a statistically significant higher mortality rate than with the mice given influenza B alone. In weanling mice, it appeared that ASA shortened the time until death; however, this difference was not statistically significant. In vitro studies demonstrated that both ASA and acetaminophen decreased the interferon-induced antiviral responses of cultured mammalian cells. Antipyretics have the potential to exacerbate the consequences of a viral infection, although the specific effects are subtle and appear to be age-related.
ST antipyretic ASA influenza B Reye's syndrome; acetaminophen toximul interaction antiviral interferon age
IT Brain, disease
Brain, disease
(Reye's syndrome; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)
IT Aging, animal
Antipyretics
Antiviral agents
Influenza B virus
Newborn

(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT Interferons

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT Anti-inflammatory agents

(nonsteroidal; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT Drug interactions

(synergistic; effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT 50-78-2, Acetylsalicylic acid

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

IT 103-90-2, Acetaminophen 37341-79-0, Toximul MP8

RL: ADV (Adverse effect, including toxicity); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)

(effects of antipyretics on mortality due to influenza B virus in a mouse model of Reye's syndrome)

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Casteels-van Daele, M; Arch Dis Child 1997, V76, P79 MEDLINE
- (2) Crocker, J; Exp Neurol 1991, V111, P95 MEDLINE
- (3) Crocker, J; Lab Invest 1986, V54, P32 CAPLUS
- (4) Davis, L; Ann Neurol 1985, V18, P556 CAPLUS
- (5) Deshmukh, D; Proc Natl Acad Sci USA 1982, V79, P7557 CAPLUS
- (6) Doran, T; J Pediatr 1989, V114, P1045 MEDLINE
- (7) Fromenty, B; Pharam Ther 1995, V67, P101 CAPLUS
- (8) Godfrey, A; N Engl J Med 1985, V313, P450
- (9) Graham, N; J Infect Dis 1990, V162, P1277 MEDLINE
- (10) Halpin, T; JAMA 1982, V248, P687 MEDLINE
- (11) Hardie, R; Arch Dis Child 1996, V74, P400 MEDLINE
- (12) Hug, G; Lab Invest 1981, V45, P89 CAPLUS
- (13) Hurwitz, E; JAMA 1987, V257, P1905 MEDLINE
- (14) Hurwitz, E; N Engl J Med 1985, V313, P849 MEDLINE
- (15) Krawchuk, S; [dissertation] Dalhousie University 1989
- (16) Lee, S; Appl Environ Microbiol 1990, V40, P787
- (17) Levy, M; Drug Saf 1997, V16, P1 MEDLINE
- (18) Linnemann, C; Pediatr Res 1979, V13, P44 CAPLUS
- (19) Macdonald, M; Pediatr Res 1984, V18, P181 CAPLUS
- (20) Malamy, J; Science 1990, V250, P1002
- (21) Mantel, N; Cancer Chemother Rep 1966, V50, P163 MEDLINE
- (22) Metraux, J; Science 1990, V250, P1004 CAPLUS
- (23) Murphy, M; Biochim Biophys Acta 1996, V1315, P208 CAPLUS
- (24) Murphy, M; Biochim Biophys Acta 1997, V1361, P103 CAPLUS
- (25) Oehen, S; Science 1991, V251, P195 MEDLINE
- (26) Orłowski, J; Cleve Clin J Med 1990, V57, P323 MEDLINE
- (27) Poss, W; Arch Pediatr Adolesc Med 1994, V148, P879 MEDLINE
- (28) Remington, P; Pediatrics 1986, V77, P93 MEDLINE
- (29) Reye, R; Lancet 1963, V2, P749
- (30) Roe, C; Reye's syndrome Round Table Series, no 8 1988, P85
- (31) Rogers, M; Pediatrics 1985, V75, P260 MEDLINE
- (32) Rosenberg, D; South Med J 1977, V70, P660 MEDLINE

- (33) Rozee, K; CMAJ 1982, V126, P798 MEDLINE
- (34) Rozee, K; Canadian Pediatric Society meeting 1987
- (35) Shindell, S; Lancet 1993, V341, P119 MEDLINE
- (36) Smith, T; Scott Med J 1996, V41, P409
- (37) Stanley, E; JAMA 1975, V231, P1248 MEDLINE
- (38) Starko, K; Pediatrics 1980, V66, P859 MEDLINE
- (39) Stumpf, D; Brain Dev 1995, V17(Suppl), P77
- (40) Trauner, D; Neurology 1988, V38, P239
- (41) Vesentin, M; Drug Metab Rev 1995, V27, P517
- (42) Waldman, R; JAMA 1982, V247, P3089 MEDLINE
- (43) Yamashita, F; Reye's syndrome IV 1985, P47

=> e vascular

E1	1	VASCULAIRTY/BI
E2	1	VASCULAIZATION/BI
E3	114286 -->	VASCULAR/BI
E4	2	VASCULARACTIVE/BI
E5	1	VASCULARATURE/BI
E6	2	VASCULARCHANGES/BI
E7	2	VASCULARCOMPLICATIONS/BI
E8	3	VASCULARE/BI
E9	1	VASCULARENDODERMIS/BI
E10	1	VASCULARENDOTHELIAL/BI
E11	1	VASCULARENDOTHELIUM/BI
E12	1	VASCULARETASTATIC/BI

=> s e3

L11 114286 VASCULAR/BI

=> s l11 and l5

10725 L2

L12 52 L11 AND L5

=> d l12 20-52

L12 ANSWER 20 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:338762 CAPLUS

DN 134:362292

TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

IN Farr, Spencer

PA Phase-1 Molecular Toxicology, USA

SO PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103
	WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-165398P P 19991105

L12 ANSWER 21 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:82583 CAPLUS
 DN 134:295096
 TI Anti-microinflammatory lipid signals generated from dietary n-3 fatty acids via cyclooxygenase-2 and transcellular processing: A novel mechanism for NSAID and n-3 PUFA therapeutic actions
 AU Serhan, Charles N.; Clish, C. B.; Brannon, J.; Colgan, S. P.; Gronert, K.; Chiang, N.
 CS Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
 SO Journal of Physiology and Pharmacology (2000), 51(4, Pt. 1), 643-654
 CODEN: JPHPEI; ISSN: 0867-5910
 PB Polish Physiological Society
 DT Journal
 LA English
 RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:789314 CAPLUS
 DN 134:235500
 TI Circulating soluble **vascular** adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease
 AU Kurkijarvi, Riikka; Yegutkin, Gennady G.; Gunson, Bridget K.; Jalkanen, Sirpa; Salmi, Marko; Adams, David H.
 CS Liver Research Laboratories, MRC Centre for Immune Regulation at the University of Birmingham, Birmingham, UK
 SO Gastroenterology (2000), 119(4), 1096-1103
 CODEN: GASTAB; ISSN: 0016-5085
 PB W. B. Saunders Co.
 DT Journal
 LA English
 RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:742909 CAPLUS
 DN 134:28791
 TI Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing
 AU Serhan, Charles N.; Clish, Clary B.; Brannon, Jessica; Colgan, Sean P.; Chiang, Nan; Gronert, Karsten
 CS Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
 SO Journal of Experimental Medicine (2000), 192(8), 1197-1204
 CODEN: JEMEA; ISSN: 0022-1007
 PB Rockefeller University Press
 DT Journal
 LA English
 RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:783925 CAPLUS
 DN 132:22753
 TI Preparation of N-(arylsulfonylphenyl)-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives for the elevation of pyruvate

dehydrogenase (PDH) activity
 IN Butlin, Roger John; Nowak, Thorsten; Burrows, Jeremy Nicholas; Block,
 Michael Howard
 PA Zeneca Limited, UK
 SO PCT Int. Appl., 211 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9962506	A1	19991209	WO 1999-GB1669	19990526
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				
	DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,				
	KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,				
	MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,				
	TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,				
	RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				
	ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,				
	CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2331685	AA	19991209	CA 1999-2331685	19990526
	AU 9940524	A1	19991220	AU 1999-40524	19990526
	AU 740909	B2	20011115		
	BR 9910821	A	20010213	BR 1999-10821	19990526
	EP 1082110	A1	20010314	EP 1999-923767	19990526
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				
	EE 200000691	A	20020415	EE 2000-691	19990526
	JP 2002516854	T2	20020611	JP 2000-551762	19990526
	NZ 507784	A	20021025	NZ 1999-507784	19990526
	US 6498275	B1	20021224	US 2000-700370	20001115
	NO 2000006010	A	20010126	NO 2000-6010	20001128
PRAI	GB 1998-11427	A	19980529		
	WO 1999-GB1669	W	19990526		

OS MARPAT 132:22753

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 25 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:593675 CAPLUS
 DN 132:121896
 TI Effect of methionine supplementation on endothelial function, plasma
 homocysteine, and lipid peroxidation
 AU McAuley, Daniel F.; Hanratty, Colm G.; McGurk, Colm; Nugent, Ailish G.;
 Johnston, G. Dennis
 CS The Queen's University of Belfast, Belfast, BT9 7BL, UK
 SO Journal of Toxicology, Clinical Toxicology (1999), 37(4), 435-440
 CODEN: JTCTDW; ISSN: 0731-3810
 PB Marcel Dekker, Inc.
 DT Journal
 LA English

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:570523 CAPLUS
 DN 132:77379
 TI Pro-inflammatory cytokines increase the permeability of paracetamol across
 a human endothelial-smooth muscle cell bilayer model
 AU Bohlin, K.; Cotgreave, I. A.
 CS Division of Biochemical Toxicology, Institute of Environmental Medicine,

Karolinska Institute, Stockholm, Swed.

SO Scandinavian Journal of Clinical and Laboratory Investigation (1999),
59(4), 259-266

CODEN: SJCLAY; ISSN: 0036-5513

PB Scandinavian University Press

DT Journal

LA English

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 27 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:766507 CAPLUS

DN 130:29221

TI Preparation of solid porous matrixes for pharmaceutical uses

IN Unger, Evan C.

PA ImaRx Pharmaceutical Corp., USA

SO PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9851282	A1	19981119	WO 1998-US9570	19980512
	W: AU, BR, CA, CN, JP, KR, NZ				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 2002039594	A1	20020404	US 1998-75477	19980511
	AU 9873787	A1	19981208	AU 1998-73787	19980512
	EP 983060	A1	20000308	EP 1998-921109	19980512
	R: DE, FR, GB, IT, NL				
	US 2001018072	A1	20010830	US 2001-828762	20010409
PRAI	US 1997-46379P	P	19970513		
	US 1998-75477	A	19980511		
	WO 1998-US9570	W	19980512		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:341491 CAPLUS

DN 129:12742

TI Methods and compositions using thalidomide or other angiogenesis-inhibitory compound and anti-inflammatory agent for inhibition of angiogenesis

IN D'Amato, Robert J.

PA Children's Medical Center, USA

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9819649	A2	19980514	WO 1997-US20116	19971104
	WO 9819649	A3	19980625		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				

	GN, ML, MR, NE, SN, TD, TG		
	AU 9851973	A1 19980529	AU 1998-51973 19971104
	AU 746713	B2 20020502	
	EP 963200	A2 19991215	EP 1997-946884 19971104
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
	NZ 336035	A 20020328	NZ 1997-336035 19971104
	JP 2002513391	T2 20020508	JP 1998-521728 19971104
PRAI	US 1996-28708P	P 19961105	
	US 1997-963058	A 19971103	
	WO 1997-US20116	W 19971104	
OS	MARPAT 129:12742		

L12 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:733145 CAPLUS
DN 126:27859
TI Maternal medications and environmental exposures as risk factors for
gastroschisis
AU Torfs, Claudine P.; Katz, Elizabeth A.; Bateson, Thomas F.; Lam, Phung K.;
Curry, Cynthia J. R.
CS California Birth Defects Monitoring Program, Emeryville, CA, 94608-1811,
USA
SO Teratology (1996), 54(2), 84-92
CODEN: TJADAB; ISSN: 0040-3709
PB Wiley-Liss
DT Journal
LA English

L12 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:473623 CAPLUS
DN 125:158765
TI 8-Epi PGF2.alpha.: Specific analysis of an isoeicosanoid as an index of
oxidant stress in vivo
AU Delanty, N.; Reilly, M.; Pratico, D.; Fitzgerald, D. J.; Lawson, J. A.;
Fitzgerald, G. A.
CS Center Experimental Therapeutics, University Pennsylvania, Philadelphia,
PA, 19104, USA
SO British Journal of Clinical Pharmacology (1996), 42(1), 15-19
CODEN: BCPHBM; ISSN: 0306-5251
PB Blackwell
DT Journal
LA English

L12 ANSWER 31 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:68974 CAPLUS
DN 124:165193
TI Acetaminophen-induced microvascular injury in the rat liver: Protection
with misoprostol
AU Lim, Sook Ping; Andrews, Fiona Jane; O'Brien, Paul Edmond
CS Monash Medical School, Alfred Hospital, Prahran, 3181, Australia
SO Hepatology (Philadelphia) (1995), 22(6), 1776-81
CODEN: HPTLD9; ISSN: 0270-9139
PB Saunders
DT Journal
LA English

L12 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:710058 CAPLUS
DN 123:101994
TI Sulfation of acetaminophen by the perfused rat liver: The effect of red
blood cell carriage
AU Pang, K. Sandy; Barker, Ford; Simard, Andre; Schwab, Andreas J.; Goresky,

Carl A.
 CS Faculty Pharmacy, University Toronto, St. Toronto, ON, M5S 2S2, Can.
 SO Hepatology (Philadelphia) (1995), 22(1), 267-82
 CODEN: HPTLD9; ISSN: 0270-9139
 PB Saunders
 DT Journal
 LA English

L12 ANSWER 33 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:639961 CAPLUS
 DN 123:47339
 TI Glutathione depletion kinetics with acetaminophen: a simulation study
 AU Chiba, Masato; Pang, K. Sandy
 CS Faculty of Pharmacy, Univ. of Toronto, ON, Can.
 SO Drug Metabolism and Disposition (1995), 23(6), 622-30
 CODEN: DMDSAI; ISSN: 0090-9556
 PB Williams & Wilkins
 DT Journal
 LA English

L12 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:400581 CAPLUS
 DN 119:581
 TI Relaxation of rat thoracic aorta by N-nitroso compounds and nitroprusside
 and their modifications of nucleic acid bases through release of nitric
 oxide
 AU Wang, Jin Mei; Lin-Shiau, Shoei Yn; Lin, Jen Kun
 CS Coll. Med., Natl. Taiwan Univ., Taipei, Taiwan
 SO Biochemical Pharmacology (1993), 45(4), 819-25
 CODEN: BCPA6; ISSN: 0006-2952
 DT Journal
 LA English

L12 ANSWER 35 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:249623 CAPLUS
 DN 118:249623
 TI Comparison of target organs of carcinogenicity for mutagenic and
 non-mutagenic chemicals
 AU Gold, Lois Swirsky; Slone, Thomas H.; Stern, Bonnie R.; Bernstein, Leslie
 CS Life Sci. Div., Lawrence Berkeley Lab., Berkeley, CA, 94720, USA
 SO Mutation Research (1993), 286(1), 75-100
 CODEN: MUREAV; ISSN: 0027-5107
 DT Journal
 LA English

L12 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:139770 CAPLUS
 DN 118:139770
 TI Investigation of possible mechanisms of hepatic swelling and necrosis
 caused by acetaminophen in mice
 AU Welty, Stephen E.; Smith, Charles V.; Benzick, Arthur E.; Montgomery,
 Charles A.; Hansen, Thomas N.
 CS Cent. Comp. Med., Baylor Coll. Med., Houston, TX, 77030, USA
 SO Biochemical Pharmacology (1993), 45(2), 449-58
 CODEN: BCPA6; ISSN: 0006-2952
 DT Journal
 LA English

L12 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1992:625690 CAPLUS
 DN 117:225690
 TI Second pass metabolism and transport of acetylsalicylic acid and

acetaminophen in the vascularly perfused rat intestine

AU Simmons, Daryl M.
CS Sterling Winthrop Pharm. Res. Div., Rensselaer, NY, 12144, USA
SO Journal of the Pennsylvania Academy of Science (1992), 66(1), 3-8
CODEN: JPSCEY; ISSN: 1044-6753
DT Journal
LA English

L12 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:482858 CAPLUS
DN 117:82858
TI Uptake of a protein-bound polar compound, acetaminophen sulfate, by
perfused rat liver
AU Goresky, Carl A.; Pang, K. Sandy; Schwab, Andreas J.; Barker, Ford, III;
Cherry, Wendy F.; Bach, Glen G.
CS Montreal Gen. Hosp., McGill Univ. Med. Clin., Montreal, QC, H3G 1A4, Can.
SO Hepatology (Philadelphia, PA, United States) (1992), 16(1), 173-90
CODEN: HPTLD9; ISSN: 0270-9139
DT Journal
LA English

L12 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:654164 CAPLUS
DN 115:254164
TI [Ala IL-8] as a leukocyte adhesion inhibitor, and its recombinant
production, purification, and activity
IN Gimbrone, Michael A., Jr.; Obin, Martin S.; Baker, Joffre B.; Hebert,
Caroline Alice
PA Brigham and Women's Hospital, USA; Genentech, Inc.
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9108231	A1	19910613	WO 1990-US6918	19901127
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU	9169523	A1	19910626	AU 1991-69523	19901127
EP	504257	A1	19920923	EP 1991-901110	19901127
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL				
JP	05503512	T2	19930610	JP 1991-501540	19901127
US	5451399	A	19950919	US 1992-964525	19921019
PRAI	US 1989-443131		19891129		
	WO 1990-US6918		19901127		

L12 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:400372 CAPLUS
DN 111:372
TI Pronounced reduction of in vivo prostacyclin synthesis in humans by
acetaminophen (paracetamol)
AU Green, K.; Drvota, V.; Vesterqvist, O.
CS Dep. Clin. Chem. Blood Coagulation, Karolinska Hosp., Stockholm, S-104 01,
Swed.
SO Prostaglandins (1989), 37(3), 311-15
CODEN: PRGLBA; ISSN: 0090-6980
DT Journal
LA English

L12 ANSWER 41 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:107543 CAPLUS

DN 110:107543
TI Effects of perfusate flow rate on measured blood volume, Disse space,
intracellular water space, and drug extraction in the perfused rat liver
preparation: characterization by the multiple indicator dilution technique
AU Pang, K. Sandy; Lee, Wai Fong; Cherry, Wendy F.; Yuen, Vincent; Accaputo,
Josephine; Fayz, Shirin; Schwab, Andreas J.; Goresky, Carl A.
CS Fac. Pharm., Univ. Toronto, Toronto, ON, M5S 1A1, Can.
SO Journal of Pharmacokinetics and Biopharmaceutics (1988), 16(6), 595-632
CODEN: JPBPBJ; ISSN: 0090-466X
DT Journal
LA English

L12 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:365 CAPLUS
DN 106:365
TI The chronic hepatotoxic, tumor-promoting, and carcinogenic effects of
acetaminophen in male B6C3F1 mice
AU Hagiwara, Akihiro; Ward, Jerrold M.
CS Lab. Comp. Carcinog., Natl. Cancer Inst., Frederick, MD, 21701-1013, USA
SO Fundamental and Applied Toxicology (1986), 7(3), 376-86
CODEN: FAATDF; ISSN: 0272-0590
DT Journal
LA English

L12 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:416725 CAPLUS
DN 103:16725
TI Acetaminophen-induced hepatotoxic congestion in mice
AU Walker, Robin M.; Racz, William J.; McElligott, T. Francis
CS Dep. Pathol., Hotel Dieu Hosp., Kingston, ON, K7L 3H6, Can.
SO Hepatology (Philadelphia, PA, United States) (1985), 5(2), 233-40
CODEN: HPTLD9; ISSN: 0270-9139
DT Journal
LA English

L12 ANSWER 44 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:197486 CAPLUS
DN 102:197486
TI Effects of N-acetylcysteine on acetaminophen covalent binding and hepatic
necrosis in mice
AU Corcoran, G. B.; Racz, W. J.; Smith, C. V.; Mitchell, J. R.
CS Inst. Lipid Res., Baylor Coll. Med., Houston, TX, USA
SO Journal of Pharmacology and Experimental Therapeutics (1985), 232(3),
864-72
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

L12 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1984:150604 CAPLUS
DN 100:150604
TI Vectorial release of sulfoconjugates in the vascularly perfused mouse
small intestine
AU Wollenberg, Peter; Rummel, Walter
CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, 6650, Fed. Rep.
Ger.
SO Biochemical Pharmacology (1984), 33(2), 205-8
CODEN: BCPA6; ISSN: 0006-2952
DT Journal
LA English

L12 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1981:473286 CAPLUS
 DN 95:73286
 TI Attenuation by acetaminophen of arachidonic acid-induced coronary
 vasodilation and output of prostaglandins in the isolated rat heart
 AU Shaffer, Joel E.; Cagen, Lauren M.; Malik, Kafait U.
 CS Cent. Health Sci., Univ. Tennessee, Memphis, TN, 38163, USA
 SO European Journal of Pharmacology (1981), 72(1), 57-61
 CODEN: EJPHAZ; ISSN: 0014-2999
 DT Journal
 LA English

L12 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:90213 CAPLUS
 DN 94:90213
 TI Effects of maltitol or mannitol on gastrointestinal absorption of drugs
 AU Niwa, Hiroshi; Hikichi, Noboru; Sakurai, Eiichi; Ueda, Masataka; Fukuse,
 Gen
 CS Tohoku Coll. Pharm., Sendai, 983, Japan
 SO Yakugaku Zasshi (1980), 100(11), 1118-26
 CODEN: YKKZAJ; ISSN: 0031-6903
 DT Journal
 LA Japanese

L12 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1980:488835 CAPLUS
 DN 93:88835
 TI Quantity of serotonin, histamine and polyamine, and gastrointestinal
 absorption of drugs in magnesium sulfate-induced diarrheal state
 AU Niwa, Hiroshi; Hikichi, Noboru; Sakurai, Eiichi; Sasaki, Kazuhiko; Ueda,
 Masataka
 CS Tohoku Coll. Pharm., Sendai, Japan
 SO Yakuzaigaku (1980), 40(1), 32-41
 CODEN: YAKUA2; ISSN: 0372-7629
 DT Journal
 LA Japanese

L12 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1979:413356 CAPLUS
 DN 91:13356
 TI Quantitative measurement of the **vascular** changes produced by UV
 radiation and carrageenin using the guinea pig ear as the site of
 inflammation
 AU Woodward, D. F.; Owen, D. A. A.
 CS Res. Inst., Smith Kline and French Lab., Ltd., Welwyn Garden City/Herts.,
 UK
 SO Journal of Pharmacological Methods (1979), 2(1), 35-42
 CODEN: JPMED9; ISSN: 0160-5402
 DT Journal
 LA English

L12 ANSWER 50 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1978:130867 CAPLUS
 DN 88:130867
 TI Effects of paracetamol on livers in rats
 AU Banerjee, M.; Sengupta, M.; Das, J.; Sikdar, S.; Mitra, N. K.
 CS Dep. Pharmacol. Pathol., Univ. Coll. Med., Calcutta, India
 SO Calcutta Medical Journal (1976), 73(11-12), 119-23
 CODEN: CMJRAY; ISSN: 0008-0667
 DT Journal
 LA English

L12 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1974:201 CAPLUS
DN 80:201
TI Effect of antiinflammatory and antiproteolytic preparations on
vascular disturbances of the intestines of animals irradiated by
supralethal doses
AU Uklonskaya, L. I.; Kudryavtsev, V. D.; Sushkevich, L. N.; Cherkasov, V. F.
CS Res. Inst. Med. Radiol., Obninsk, USSR
SO Byulleten Eksperimental'noi Biologii i Meditsiny (1973), 76(8), 37-9
CODEN: BEBMAE; ISSN: 0365-9615
DT Journal
LA Russian

L12 ANSWER 52 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1957:67852 CAPLUS

DN 51:67852

OREF 51:12324f-i

TI **Vascular** and respiratory effects of some phenyl and indole
compounds related to 5-hydroxytryptamine

AU Rosell, Sune; Uvnas, Borje; Wretlind, Arvid

CS Karolinska Inst., Stockholm

SO Acta Pharmacol. Toxicol. (1957), 13, 289-300

DT Journal

LA Unavailable

=> d 112 52 all

L12 ANSWER 52 OF 52 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1957:67852 CAPLUS

DN 51:67852

OREF 51:12324f-i

TI **Vascular** and respiratory effects of some phenyl and indole
compounds related to 5-hydroxytryptamine

AU Rosell, Sune; Uvnas, Borje; Wretlind, Arvid

CS Karolinska Inst., Stockholm

SO Acta Pharmacol. Toxicol. (1957), 13, 289-300

DT Journal

LA Unavailable

CC 11H (Biological Chemistry: Pharmacology)

AB Cats anesthetized with dial, chloralose, or chloralose-urethan were used.
5-Hydroxy-2-nitrotoluene, 5-methoxy-2-nitrotoluene, and p-benzyloxyaniline
had a hypotensive effect but no influence on respiration. No effect on
blood pressure or respiration was observed after injection of
2-nitro-5-methoxy- and 2-nitro-5-benzyloxyphenylpyruvic acid,
4-acetamidophenol, p-methoxyphenylhydrazine-HCl, and Na
p-methoxydiazobenzenesulfonate. Of the indole derivs. investigated, those
producing decrease in blood pressure, bradycardia, and apnea were
2-methyl-3-(diethylaminomethyl)indole, 2-methyl-3-(pyrrolylmethyl)indole,
2-methyl-3-(piperidinomethyl)-5-chloroindole (I), 2,5-dimethyl-3-
(piperidinomethyl)indole, 2,5-dimethyl-3-(pyrrolylmethyl)indole,
2-phenyl-3-(piperidinomethyl)indole, and 5-benzyloxyindole. I was studied
further. The bradycardia, part of the hypotensive effect, and the apnea
were found to be produced through an effect on receptors located in the
region of distribution of the pulmonary artery. Indole derivs. that had
no effect on blood pressure were 2,5-dimethyl-3-
(dimethylaminomethyl)indole and 5-benzyloxyindole-2-carboxylic acid.

IT Arteries

(chemoreceptors of pulmonary, effect of phenyl and indole compds.
related to 5-hydroxytryptamine on)

IT Nerves

(chemoreceptors, effect of 5-hydroxytryptamine-related phenyl and
indole compds. on)

e.g., D SCAN or DISPLAY SCAN)

STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels

IALL ----- ALL, indented with text labels

IBIB ----- BIB, indented with text labels

IMAX ----- MAX, indented with text labels

ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)

OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations

SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms

HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms

HITRN ----- HIT RN and its text modification

HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram

HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields

FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram

FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields

KWIC ----- Hit term plus 20 words on either side

OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):bib

L13 ANSWER 1 OF 5160 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:599875 CAPLUS

TI Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-.kappa.B activation through inhibition of I.kappa.B.alpha. kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1

AU Shishodia, Shishir; Potdar, Pravin; Gairola, C. Gary; Aggarwal, Bharat B.

CS Box 143, Department of Bioimmunotherapy, Cytokine Research Laboratory, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

SO Carcinogenesis (2003), 24(7), 1269-1279

CODEN: CRNGDP; ISSN: 0143-3334

PB Oxford University Press

DT Journal

LA English

=> d his

(FILE 'HOME' ENTERED AT 14:08:00 ON 07 AUG 2003)